Proxy Statement (definitive) (def 14a)

Use these links to rapidly review the document
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No. )


Filed by the Registrant ý
Filed by a Party other than the Registrant o
Check the appropriate box:
o		Preliminary Proxy Statement
o		Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
ý		Definitive Proxy Statement
o		Definitive Additional Materials
o		Soliciting Material under §240.14a-12


OvaScience, Inc.
(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
ý	No fee required.
o	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
	(1)	Title of each class of securities to which transaction applies:
	(2)	Aggregate number of securities to which transaction applies:
	(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
	(4)	Proposed maximum aggregate value of transaction:
	(5)	Total fee paid:
o	Fee paid previously with preliminary materials.
o	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
	(1)	Amount Previously Paid:
	(2)	Form, Schedule or Registration Statement No.:
	(3)	Filing Party:
	(4)	Date Filed:

Table of Contents

OVASCIENCE, INC.
9 Fourth Avenue
Waltham, Massachusetts 02451

To our Stockholders:

You are cordially invited to attend our 2017 Annual Meeting of Stockholders. Our Annual Meeting will be held at the Westin Waltham Boston Hotel, 70 Third Avenue, Waltham, Massachusetts, on Thursday, June 8, 2017, at 11:00 a.m., local time. The attached Notice of Annual Meeting of Stockholders and proxy statement contain details of the business to be conducted at our Annual Meeting. We urge you to review these proxy materials carefully and to use this opportunity to take part in the affairs of OvaScience, Inc. by voting on the matters described in the proxy statement.

We have elected to provide our proxy materials over the Internet under the Securities and Exchange Commission's "notice and access" rules. Providing our proxy materials to stockholders electronically allows us to conserve natural resources and reduce our printing and mailing costs related to the distribution of the proxy materials. If you wish to receive paper copies of the proxy materials, you may do so by following the instructions contained in this proxy statement. The proxy statement also provides instructions on how to vote online or by telephone and includes instructions on how to receive a paper copy of the proxy materials by mail.

Your vote is important. Whether or not you plan to attend the Annual Meeting we hope you will vote as soon as possible. You may vote over the Internet, as well as by telephone, or, if you received printed proxy materials, by mailing a proxy or voting instruction card. Please review the instructions on each of your voting options described in this proxy statement, as well as in the Notice of Annual Meeting of Stockholders.

Thank you for your support of OvaScience, Inc. We look forward to seeing you at our Annual Meeting.



		Michelle Dipp, M.D., Ph.D. Executive Chair

Table of Contents

OVASCIENCE, INC.
9 Fourth Avenue
Waltham, Massachusetts 02451

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
to be held on Thursday, June 8, 2017

To our Stockholders:

NOTICE IS HEREBY GIVEN that the Annual Meeting of Stockholders (the "Annual Meeting") of OvaScience, Inc., a Delaware corporation ("OvaScience" or the "Company"), will be held at the Westin Waltham Boston Hotel, 70 Third Avenue, Waltham, Massachusetts, on Thursday, June 8, 2017, at 11:00 a.m., local time, to consider and act upon the following matters:

1.: To elect three class II directors nominated by our board of directors, each for a three-year term expiring at the 2020 annual meeting of stockholders;
2.: To ratify the appointment of Ernst & Young LLP, an independent registered public accounting firm, as our independent auditors for the fiscal year ending December 31, 2017;
3.: To approve by an advisory vote the compensation of our named executive officers, as disclosed in this proxy statement; and
4.: To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.

Stockholders of record at the close of business on April 10, 2017, the record date for the Annual Meeting, are entitled to notice of, and to vote at, the Annual Meeting or any adjournment thereof. Your vote is important regardless of the number of shares you own. If you are a stockholder of record, please vote in one of these ways:

(1): Vote over the Internet. You may vote your shares by following the "Vote by Internet" instructions on the enclosed proxy card or on your Notice of Internet Availability of Proxy Materials.
(2): Vote by telephone. You may vote your shares by following the "Vote by Phone" instructions on the enclosed proxy card.
(3): Vote by mail. If you received your proxy materials by mail, you may vote by completing and signing the proxy card delivered with those materials and returning it in the postage-paid envelope we provided.

If your shares are held in "street name," that is, held for your account by a broker or other nominee, you will receive instructions from the holder of record that you must follow for your shares to be voted.

We encourage all stockholders to attend the Annual Meeting in person. You may obtain directions to the location of the Annual Meeting on our website at www.ovascience.com . Whether or not you plan to attend the Annual Meeting in person, we urge you to take the time to vote your shares.


		By Order of the Board of Directors,

		Michelle Dipp, M.D., Ph.D. Executive Chair and Corporate Secretary

Waltham, Massachusetts
April 25, 2017

Table of Contents

Table of Contents

		Page

Important Information About the Annual Meeting and Voting			1
Householding of Annual Meeting Materials			8
Expenses and Solicitation			9
Corporate Governance			10
General			10
Our Board of Directors			10
Board Leadership Structure			14
Board Committees			15
Board Meetings and Attendance			18
Compensation Committee Interlocks and Insider Participation			18
Board Processes			18
Executive Officers			20
Certain Relationships and Related Transactions			21
Policies and Procedures for Related Person Transactions			21
Related Person Transactions			22
Compensation Discussion and Analysis			23
Compensation Committee Report			34
Executive Compensation			35
Overview			35
Summary Compensation Table			35
2016 Fiscal Year Grants Of Plan-Based Awards			36
Outstanding Equity Awards at Fiscal Year End			37
Option Exercises and Stock Vested in 2016			38
Employment Agreements and Separation Agreements			38
2016 Bonus Payments			40
Potential Payments upon Termination or Change in Control			41
401(k) Retirement Plan			44
Securities Authorized for Issuance Under Our Equity Compensation Plans			45
Director Compensation			46
Audit Related Matters			48
Audit Committee Report			48
Audit Fees and Services			48
Policy for Approval of Services			49
Matters to be Voted On			50
Proposal 1: Election of Class II Directors			50
Proposal 2: Ratification of Appointment of Independent Auditors			51
Proposal 3: Approval of Advisory Vote on the Compensation of Named Executive Officers			52
Ownership of Our Common Stock			54
Security Ownership of Certain Beneficial Owners and Management			54
Section 16(a) Beneficial Ownership Reporting Compliance			57
Other Matters			58
Stockholder Proposals			58
Deadline for Submission of Stockholder Proposals for 2018 Annual Meeting			58

Table of Contents

OVASCIENCE, INC.
9 Fourth Avenue
Waltham, MA 02142
PROXY STATEMENT
FOR THE 2017 ANNUAL MEETING OF STOCKHOLDERS
to be held on Thursday, June 8, 2017

This proxy statement and the enclosed proxy card are being furnished in connection with the solicitation of proxies by the Board of OvaScience, Inc., or the Board, for use at the 2017 Annual Meeting of Stockholders to be held on Thursday, June 8, 2017 at the Westin Waltham Boston Hotel, 70 Third Avenue, Waltham, Massachusetts, at 11:00 a.m., local time, and at any adjournment or postponement thereof.

All proxies will be voted in accordance with the instructions contained in those proxies. If no choice is specified, the proxies will be voted in favor of the matters set forth in the accompanying Notice of Annual Meeting of Stockholders.

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS
For the Annual Meeting of Stockholders to be Held on Thursday, June 8, 2017:

The proxy materials, which include our proxy statement for the Annual Meeting, our 2016 Annual Report, which includes our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, and, if you received a paper copy of these materials, a proxy card or voting instruction card, are available for viewing, printing and downloading at www.proxyvote.com .

A copy of our proxy materials will be furnished without charge to any stockholder upon oral or written request to OvaScience, Inc., 9 Fourth Avenue, Waltham, Massachusetts 02451, Attention: Investor Relations, Telephone: (617) 500-2802 or pursuant to the instructions included in this proxy statement.

This proxy statement and our Annual Report on Form 10-K for the fiscal year ended December 31, 2016 are also available on the Securities and Exchange Commission's website at www.sec.gov.

IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING AND VOTING


Q.		Why did I receive these proxy materials?		A.		We are providing these proxy materials to you in connection with the solicitation by our Board of proxies to be voted at our Annual Meeting, to be held at the Westin Waltham Boston Hotel, 70 Third Avenue, Waltham, Massachusetts, on Thursday, June 8, 2017 at 11:00 a.m., local time. As a stockholder of OvaScience, you are invited to attend our Annual Meeting and are entitled and requested to vote on the proposals described in this proxy statement.

Table of Contents


Q.	What is included in the proxy materials?	A.	The proxy materials include our proxy statement for the Annual Meeting, our 2016 annual report, which includes our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, and, if you received a paper copy of these materials, a proxy card or voting instruction card. If you received a Notice of Internet Availability of Proxy Materials, please see "Why did I receive a Notice of Internet Availability of Proxy Materials instead of a paper copy of the proxy materials?" below.
Q.	Why did I receive a Notice of Internet Availability of Proxy Materials instead of a paper copy of the proxy materials?	A.	In accordance with rules adopted by the SEC, we may furnish proxy materials, including this proxy statement and our 2016 annual report to stockholders, to our stockholders by providing access to such documents on the Internet instead of mailing printed copies. Most stockholders will not receive printed copies of the proxy materials unless they request them. Instead, the Notice of Internet Availability of Proxy Materials, which will be mailed to our stockholders commencing on or about April 27, 2017, will instruct you as to how you may access and review all of the proxy materials on the Internet. The Notice of Internet Availability of Proxy Materials also instructs you as to how you may submit your proxy on the Internet. If you would like to receive a paper copy of our proxy materials, you should follow the instructions for requesting such materials in the Notice of Internet Availability of Proxy Materials.
Q.	Who can vote at the Annual Meeting?	A.	To be entitled to vote, you must have been a stockholder of record at the close of business on April 10, 2017, the record date for our Annual Meeting. The holders of 35,662,124 shares of our common stock outstanding as of the record date are entitled to vote at the Annual Meeting.
			If you were a stockholder of record on April 10, 2017, you are entitled to vote all of the shares that you held on that date at the Annual Meeting and at any postponement or adjournment thereof.
Q.	What are the voting rights of the holders of common stock?	A.	Each outstanding share of our common stock will be entitled to one vote on each matter considered at the Annual Meeting.

Table of Contents


Q.	How do I vote?	A.	If your shares are registered directly in your name, you may vote:
			(1)	Over the Internet: Go to the website of our tabulator, Broadridge Financial Solutions, Inc., at www.proxyvote.com. Have your proxy card in hand when you access the website and follow the instructions to obtain your records and to create an electronic voting instruction form. You must specify how you want your shares voted or your Internet vote cannot be completed and you will receive an error message. Your shares will be voted according to your instructions. You must submit your Internet proxy before 11:59 p.m., Eastern Time, on Wednesday, June 7, 2017, the day before the Annual Meeting, for your proxy to be valid and your vote to count.
			(2)	By Telephone: Call 1-800-690-6903, toll free from the United States, Canada and Puerto Rico, and follow the recorded instructions. You must specify how you want your shares voted and confirm your vote at the end of the call or your telephone vote cannot be completed. Your shares will be voted according to your instructions. You must submit your telephonic proxy before 11:59 p.m., Eastern Time, on Wednesday, June 7, 2017, the day before the Annual Meeting, for your proxy to be valid and your vote to count.
			(3)	By Mail: If you received your proxy materials by mail, complete and sign your proxy card and mail it to Broadridge in the postage prepaid envelope we provided. Broadridge must receive the proxy card not later than Wednesday, June 7, 2017, the day before the Annual Meeting, for your proxy to be valid and your vote to count. Your shares will be voted according to your instructions. If you do not specify how you want your shares voted, the persons named as proxies will follow our board's recommendations and vote your shares:
				• "FOR" the election of all director nominees;

Table of Contents


								• "FOR" the ratification of the appointment of Ernst & Young LLP as our independent auditors for the fiscal year ending December 31, 2017;
								• "FOR" the approval of the compensation of our Named Executive Officers (as defined herein);
								• On any other matters properly brought before the Annual Meeting, in accordance with the best judgment of the named proxies.
						(4)		In Person at the Meeting: If you attend the Annual Meeting, you may deliver your completed proxy card in person or you may vote by completing a ballot, which we will provide to you at the meeting.
						If your shares are held in "street name," meaning they are held for your account by a bank, broker or other nominee, you may vote:
						(A)		Over the Internet or by Telephone: You will receive instructions from your bank, broker or other nominee if they permit Internet or telephone voting. You should follow those instructions.
						(B)		By Mail: You will receive instructions from your bank, broker or other nominee explaining how you can vote your shares by mail. You should follow those instructions.
						(C)		In Person at the Meeting: Contact your bank, broker or other nominee who holds your shares to obtain a broker's proxy card and bring it with you to the Annual Meeting. A broker's proxy is not the form of proxy enclosed with this proxy statement. You will not be able to vote shares you hold in street name in person at the Annual Meeting unless you have a proxy from your bank, broker or other nominee issued in your name giving you the right to vote your shares.

Table of Contents


Q.	Can I change my vote?	A.	If your shares are registered directly in your name, you may revoke your proxy and change your vote at any time before the Annual Meeting. To do so, you must do one of the following:
			(1)	Vote over the Internet or by telephone as instructed above. Only your latest Internet or telephone vote is counted. You may not change your vote over the Internet or by telephone after 11:59 p.m., Eastern Time, on Wednesday, June 7, 2017.
			(2)	Sign a new proxy and submit it as instructed above. Only your latest dated proxy, received by Broadridge not later than Wednesday, June 7, 2017, will be counted.
			(3)	Attend the Annual Meeting, request that your proxy be revoked and vote in person as instructed above. Attending the Annual Meeting will not revoke your Internet vote, telephone vote or proxy, as the case may be, unless you specifically request it.
			If your shares are held in street name, you may submit new voting instructions by contacting your bank, broker or other nominee. You may also vote in person at the Annual Meeting if you obtain a broker's proxy as described in the answer above.
Q.	Will my shares be voted if I do not return my proxy?	A.	If your shares are registered directly in your name, your shares will not be voted if you do not vote over the Internet, by telephone, by returning your proxy or by ballot at the Annual Meeting.
			If your shares are held in street name, your bank, broker or other nominee may, under certain circumstances, vote your shares if you do not timely return your proxy. Banks, brokers or other nominees can vote their customers' unvoted shares on discretionary matters but cannot vote such shares on non-discretionary matters. If you do not timely return a proxy to your bank, broker or other nominee to vote your shares, your bank, broker or other nominee may, on discretionary matters, either vote your shares or leave your shares unvoted. Your bank, broker or other nominee cannot vote your shares on any non-discretionary matter.

Table of Contents


			The election of directors (Proposal 1) and advisory vote on the compensation of Named Executive Officers (Proposal 3) are non-discretionary matters. The ratification of the appointment of our independent auditors (Proposal 2) is a discretionary matter. We encourage you to provide voting instructions to your bank, broker or other nominee by giving your proxy to them. This ensures that your shares will be voted at the Annual Meeting according to your instructions. You should receive directions from your bank, broker or other nominee about how to submit your proxy to them at the time you receive this proxy statement.
Q.	How many shares must be present to hold the Annual Meeting?	A.	A majority of our outstanding shares of common stock entitled to vote must be present to hold the Annual Meeting and conduct business. This is called a quorum. For purposes of determining whether a quorum exists, we count as present any shares that are voted over the Internet, by telephone, by completing and submitting a proxy or that are represented in person at the meeting. Further, for purposes of establishing a quorum, we will count as present shares that a stockholder holds even if the stockholder votes to abstain or only votes on one of the proposals. In addition, we will count as present shares held in street name by banks, brokers or nominees who indicate on their proxies that they do not have authority to vote those shares on Proposal 1. If a quorum is not present, we expect to adjourn the Annual Meeting until we obtain a quorum.
Q.	What vote is required to approve each matter and how are votes counted?	A.	Proposal 1—Election of Class II Directors The three nominees for director receiving the highest number of votes FOR election will be elected as directors. This is called a plurality. Proposal 1 is a non-discretionary matter. Therefore, if your shares are held by your bank, broker or other nominee in street name and you do not vote your shares, your bank, broker or other nominee cannot vote your shares on Proposal 1. Shares held in street name by banks, brokers or nominees who indicate on their proxies that they do not have authority to vote the shares on Proposal 1 will not be counted as votes FOR or WITHHELD from any nominee and will be treated as "broker non-votes." As a result, broker non-votes will have no effect on the voting on Proposal 1. With respect to Proposal 1, you may:
			• vote FOR all nominees;

Table of Contents


						• vote FOR one or more nominee(s) and WITHHOLD your vote from the other nominee(s); or
						• WITHHOLD your vote from all nominees.
						Votes that are withheld will not be included in the vote tally for the election of directors and will not affect the results of the vote.
						Proposal 2—Ratification of Appointment of Independent Auditors To approve Proposal 2, stockholders holding a majority of the votes cast affirmatively or negatively on the matter must vote FOR the proposal. Proposal 2 is a discretionary matter. If your shares are held by your bank, broker or other nominee in street name and you do not vote your shares, your bank, broker or other nominee may vote your unvoted shares on Proposal 2. If you vote to ABSTAIN on Proposal 2, your shares will not be voted FOR or AGAINST the proposal and will also not be counted as votes cast or shares voting on the proposal. As a result, voting to ABSTAIN will have no effect on the voting on Proposal 2.
						Although stockholder approval of our Audit Committee's appointment of Ernst & Young LLP as our independent auditors for the year ending December 31, 2017 is not required, we believe that it is advisable to give stockholders an opportunity to ratify this appointment. If this proposal is not approved at the Annual Meeting, our Audit Committee may reconsider its appointment of Ernst & Young LLP as our independent auditors for the year ending December 31, 2017.
						Proposal 3—Approval of Advisory Vote on the Compensation of Named Executive Officers

Table of Contents


			To approve Proposal 3, stockholders holding a majority of the votes cast affirmatively or negatively on the matter must vote FOR the proposal. Proposal 3 is a non-discretionary matter . Therefore, if your shares are held by your bank, broker or other nominee in street name and you do not vote your shares, your bank, broker or other nominee cannot vote your shares on Proposal 3. Shares held in street name by banks, brokers or nominees who indicate on their proxies that they do not have authority to vote the shares on Proposal 3 will not be counted as votes FOR or AGAINST the proposal and will be treated as "broker non-votes." As a result, broker non-votes and voting to ABSTAIN will have no effect on the voting on Proposal 3. Although the advisory vote is non-binding, the Compensation Committee and the Board will review the voting results and take them into consideration when making future decisions regarding executive compensation.
Q.	Are there other matters to be voted on at the Annual Meeting?	A.	We do not know of any matters that may come before the Annual Meeting other than the above described Proposals 1 through 3. If any other matters are properly presented at the Annual Meeting, the persons named in the accompanying proxy intend to vote, or otherwise act, in accordance with their judgment on the matter.
Q.	Where can I find the voting results?	A.	We will report the voting results in a Current Report on Form 8-K within four business days following the adjournment of our Annual Meeting.
Q.	What are the costs of soliciting these proxies?	A.	We will bear the cost of soliciting proxies. In addition to these proxy materials, our directors, officers and employees may solicit proxies by telephone, e-mail, facsimile and in person, without additional compensation. We may reimburse brokers or persons holding stock in their names, or in the names of their nominees, for their expenses in sending proxies and proxy material to beneficial owners.

Householding of Annual Meeting Materials

Some banks, brokers and other nominee record holders may be participating in the practice of "householding" proxy statements and annual reports. This means that only one copy of our proxy statement and annual report to stockholders may have been sent to multiple stockholders in your household. We will promptly deliver a separate copy of either document to you upon written or oral request to OvaScience, Inc., 9 Fourth Avenue, Waltham, Massachusetts 02451, Attention: Investor Relations, Telephone: (617) 500-2802. If you want to receive separate copies of the proxy statement or annual report to stockholders in the future, or if you are receiving multiple copies and would like to

Table of Contents

receive only one copy per household, you should contact your bank, broker or other nominee record holder, or you may contact us at the above address and phone number.

Expenses and Solicitation

The cost of solicitation of proxies will be borne by us, and in addition to soliciting stockholders by mail through our regular employees, we may request banks, brokers, and other custodians, nominees and fiduciaries to solicit their customers who have stock of our company registered in the names of a nominee and, if so, we will reimburse such banks, brokers, and other custodians, nominees and fiduciaries for their reasonable out-of-pocket costs. Solicitation by our officers and employees may also be made of some stockholders in person or by mail, telephone, e-mail, or other form of electronic communication following the original solicitation. We have engaged The Proxy Advisory Group, LLC to advise us on certain proposals in this proxy statement and to assist in the solicitation of proxies and provide related advice and informational support, for a services fee and the reimbursement of customary disbursements that are not expected to exceed $22,500 in the aggregate.

Table of Contents

CORPORATE GOVERNANCE

General

We believe that good corporate governance is important to ensure that OvaScience is managed for the long-term benefit of our stockholders. This section describes key corporate governance guidelines and practices that we have adopted.

We have adopted a written Code of Business Conduct and Ethics, which applies to all of our officers, directors and employees. We have also adopted charters for our Audit Committee, our Compensation Committee and our nominating and governance committee, and Corporate Governance Guidelines. We have posted copies of our Code of Business Conduct and Ethics, Corporate Governance Guidelines and committee charters on the Corporate Governance page of the Investors section of our website, ir.ovascience.com , which you can access free of charge. We intend to disclose on our website any amendments to, or waivers from, our Code of Business Conduct and Ethics required to be disclosed by law or by the rules of The Nasdaq Stock Market.

Our Board of Directors

Members of the Board of Directors

Set forth below for each director, including the class II director nominees, is information as of April 1, 2017 with respect to his or her (a) name and age, (b) positions and offices at OvaScience, if any, (c) principal occupation and business experience for the past five years, (d) directorships, if any, of other publicly-held companies during the past five years, and (e) the year such person became a member of our Board. We have also included information below regarding each director's specific experience, qualifications, attributes and skills that led our board to conclude that he or she should serve as a director. In addition, we believe that all of our directors and nominees possess the attributes or characteristics described in "Board Processes—Director Nomination Process" on page 14 that we expect of each director.

Name		Position

Michelle Dipp, M.D., Ph.D.	40	Executive Chair
Richard Aldrich(3)	62	Independent Director Lead
Jeffrey D. Capello(1)	52	Director
Mary Fisher(2)	55	Director
Marc Kozin(3)(4)	55	Director
Thomas Malley(1)(2)	48	Director
John Sexton, Ph.D.(4)	74	Director
John Howe, III, M.D.(1)(2)(4)	74	Director

(1): Member of the Audit Committee
(2): Member of the Compensation Committee
(3): Member of the Nominating and Corporate Governance Committee
(4): Member of the Global Strategy Committee

Michelle Dipp, M.D., Ph.D. co-founded our company in April 2011. She has served as a member of our Board since July 2011, our Chief Executive Officer from June 2011 until July 2016, our President from September 2011 until December 2014 and our Executive Chair since January 2016. Dr. Dipp has served as a partner of Longwood Fund, LP, a venture capital investment fund, since 2010. From 2008 to 2009, Dr. Dipp served as vice president and then, from 2009 to 2011, senior vice president and head of the Centre of Excellence For External Drug Discovery (CEEDD), a business development unit at

Table of Contents

GlaxoSmithKline, a pharmaceutical and healthcare company. Prior to that, she was a founding employee of Sirtris Pharmaceuticals, Inc., a pharmaceutical company, where she served as vice president of corporate development from 2005 to 2008. Dr. Dipp serves on the Beth Israel Deaconess Medical Center Board of Trustees. Dr. Dipp holds an M.D. from Oxford University Medical School and a Ph.D. in physiology from the University of Oxford. We believe that Dr. Dipp is qualified to serve on our Board due to her scientific expertise and her experience in the life sciences industry as an entrepreneur and venture capitalist.

Richard Aldrich co-founded our company in a non-operational role in April 2011. He has served as a member of our Board since July 2011 and served as the Chairman of our Board from March 2012 until January 2016. In March 2016, Mr. Aldrich was appointed as Independent Lead Director of the Board by the independent directors. Mr. Aldrich is a co-founder and partner of Longwood Fund, LP, a venture capital investment fund. He has co-founded and helped to build several successful biotech companies including Sirtris Pharmaceuticals, Inc. (acquired by GlaxoSmithKline in 2008); Concert Pharmaceuticals, Inc., where he serves as chairman of the board; Alnara Pharmaceuticals, Inc. (acquired by Eli Lilly in 2010); Verastem, Inc.; and Flex Pharma, Inc., a biotechnology company developing treatments for symptoms associated with neuromuscular conditions. Mr. Aldrich also serves on the board of directors of Mitobridge, Inc. and Colorescience, Inc. Mr. Aldrich previously served on the board of directors of PTC Therapeutics, Inc. from March 2013 until June 2015. Prior to co-founding Longwood, he was General Partner of RA Capital, a biotechnology investment fund he co-founded in 2001. Mr. Aldrich was also a founding employee of Vertex Pharmaceuticals, Inc., where he held the position of Senior Vice President and Chief Business Officer and managed all commercial and operating functions from 1989 to 2001. Prior to joining Vertex, Mr. Aldrich held several management positions at Biogen, Inc. Mr. Aldrich received his undergraduate degree from Boston College and an M.B.A. from the Amos Tuck School at Dartmouth College. We believe that Mr. Aldrich is qualified to serve on our Board due to his experience in the life sciences industry as an entrepreneur and venture capitalist and his service on the boards of directors of other life sciences companies.

Jeffrey D. Capello has served as a member of our Board since March 2012. Mr. Capello is the Chief Executive Officer and founder of Monomoy Advisors, which focuses on helping companies drive shareholder value. From July 2014 to May 2015, Mr. Capello served as the Chief Financial Officer of Ortho-Clinical Diagnostics, which was acquired by the Carlyle Group from Johnson & Johnson, with responsibility for global finance and business development. Prior to his role at Ortho-Clinical Diagnostics, Mr. Capello served as Chief Financial Officer and Executive Vice President of Boston Scientific from March 2010 to March 2014. At Boston Scientific, Mr. Capello was responsible for the worldwide management of Boston Scientific's finance, information systems, business development and corporate strategy functions. Mr. Capello joined Boston Scientific in June 2008 and served as Senior Vice President and Chief Accounting Officer until March 2010. Prior to joining Boston Scientific, he was the Senior Vice President and Chief Financial Officer with responsibilities for global finance and business development at PerkinElmer, Inc. from 2006 to 2008. Prior to that, he served as PerkinElmer's vice president of finance, corporate controller and treasurer from 2002 to 2006 and vice president, finance, corporate controller, chief accounting officer and treasurer from 2001 to 2005. Prior to his tenure at PerkinElmer, Mr. Capello was a Partner at PricewaterhouseCoopers LLP, both in the United States and in the Netherlands. Mr. Capello is a board member of Flex Pharma, Inc., a biotechnology company developing treatments for symptoms associated with neuromuscular conditions. Previously, Mr. Capello was a member of the Board of Sirtris Pharmaceuticals, Inc., which was acquired by GlaxoSmithKline in 2008, and served as both a member and the Chair of its audit committee. Mr. Capello holds a B.S. degree in business administration from the University of Vermont and an M.B.A. degree from Harvard Business School. Mr. Capello is also a certified public accountant. We believe that Mr. Capello is qualified to serve on our Board due to his experience in the medical device and healthcare technology industries, his accounting background and his service on the boards of directors of other life sciences companies.

Table of Contents

Mary Fisher has served as a member of our Board since June 2013. Ms. Fisher also serves as Chief Executive Officer and Director at Colorescience, Inc., a former division of SkinMedica, Inc., where she served as Chief Executive Officer from April 2008 to December 2012, when she led the sale of the company to Allergan, Inc. Prior to joining SkinMedica, Ms. Fisher was the Chief Operating Officer of Acorda Therapeutics, Inc., a biotechnology company focused on developing products for the treatment of central nervous system disorders, with responsibility for corporate strategy and business development, financial planning, sales and marketing, and manufacturing. Previously, Ms. Fisher was Vice President, Strategic Healthcare and Commercial Operations for Cephalon, Inc., with responsibility for product planning and marketing, managed care sales, and manufacturing. Her earlier experience includes positions at Immunex Corp. and Boehringer Ingelheim. She is also a member of the board of directors of Zeltiq Aesthetics, Inc., a publicly-traded medical technology company, and Neuroscience Nursing Foundation. We believe that Ms. Fisher is qualified to serve on our Board based on her more than 25 years of experience in the pharmaceutical and biotechnology industries, including her executive experience.

Marc Kozin has served as a member of our Board since January 2014. Mr. Kozin has been a Senior Advisor to L.E.K. Consulting, a global strategy consulting firm, since July 2011. Prior to that, Mr. Kozin served as president of L.E.K.'s North American practice for 15 years. Mr. Kozin currently serves as a member of the board of directors of UFP Technologies, Inc., a designer and manufacturer of engineered packaging solutions and engineered component products, Endocyte, Inc., a biotechnology company developing treatments for cancer and inflammatory diseases, Flex Pharma, Inc., a biotechnology company developing treatments for symptoms associated with neuromuscular conditions, and two privately-held companies. Mr. Kozin previously served as a member of the board of directors of DYAX Corp., a biopharmaceutical company, from January 2012 until January 2016. He also serves on the strategic advisory board for Healthcare Royalty Partners, a global healthcare investment firm. Mr. Kozin holds a B.A., with distinction, in economics from Duke University and an M.B.A., with distinction, from The Wharton School, University of Pennsylvania. We believe that Mr. Kozin is qualified to serve on our Board due to his nearly 30 years of experience in corporate and business unit strategy consulting, merger and acquisition advisory services, and value management both domestically and internationally.

Thomas Malley has served as a member of our Board since October 2012. Since May 2007, Mr. Malley has served as President of Mossrock Capital, LLC, a private investment firm. From April 1991 to May 2007, Mr. Malley served with Janus Mutual Funds as an analyst for eight years and as a vice president and portfolio manager for the Janus Global Life Sciences Fund for eight years. He serves on the board of directors of Kura Oncology, Inc. and BeiGene, Ltd., both biotechnology companies. He previously served as a director of Puma Biotechnology, Inc. from 2011 to 2015, Synageva BioPharma Corp. from 2006 to 2015 and Cougar Biotechnology, Inc. from 2007 to 2009. Mr. Malley holds a B.S. in biology from Stanford University and has been a chartered financial analyst since 1994. We believe that Mr. Malley is qualified to serve on our Board due to his investment and financial experience in the biotechnology industry and his service on the boards of directors of other life sciences companies.

John Sexton, Ph.D. has served as a member of our Board since April 2015. Dr. Sexton is President Emeritus of New York University. He served as the fifteenth President of NYU from 2001 until 2015. He is a Fellow of the American Academy of Arts and Sciences, a member of the Council on Foreign Relations, and a past member of the Executive Committee of the Association of American Universities. He previously served as the Chairman of the Board of the Federal Reserve Bank of New York and Chair of the Federal Reserve Systems Council of Chairs. He was awarded the TIAA-CREF Hesburgh Award for Leadership Excellence, the Foreign Policy Association Medal, the NASPA President's Award for advancing the quality of student life at NYU, and was named one of the "Top Ten College Presidents" by TIME Magazine. Earlier in his career at NYU, he was the Dean and Benjamin Butler Professor of Law at NYU School of Law. Prior to NYU, Dr. Sexton was Law Clerk to Chief Justice

Table of Contents

Warren Burger of the United States Supreme Court and to Judges David Bazelon and Harold Leventhal of the United States Court of Appeals. Additionally, Dr. Sexton served as Special Master Supervising Pretrial Proceedings in the Love Canal Litigation. He also served as Professor of Religion and Department Chair at Saint Francis College. Dr. Sexton is a published author of several books, chapters, articles and Supreme Court briefs. Dr. Sexton holds a B.A. in History from Fordham College, an M.A. in Comparative Religion and a Ph.D. in History of American Religion from Fordham University, and a J.D. from Harvard Law School. We believe that Dr. Sexton is qualified to serve on our Board due to his executive experience and with global partnerships.

John Howe, III, M.D. has served as a member of our Board since June 2015. Dr. Howe is a recognized expert in international medicine and is a humanitarian leader. From 2001 through 2015, he served as the President and Chief Executive Officer of Project HOPE, an international health education and humanitarian assistance foundation, which operates more than 70 programs in 45 countries on five continents. During Dr. Howe's tenure, Project HOPE expanded its areas of distributing medicine, treating infectious diseases and non-communicable diseases, and promoting the health education and life improvement of women and children. Before Project HOPE, Dr. Howe held the Distinguished Chair in Health Policy at The University of Texas Health Science Center at San Antonio; he served as the Center's chief executive from 1985 through 2000 and is currently the President Emeritus. He is a board member of BB&T Bank, the Chinese Center for Communicable Disease Control and Prevention, the John E. Fogarty International Center at the National Institutes of Health and the Texas Biomedical Research Institute, among others. Among Dr. Howe's numerous honors and awards are the U.S. Army's Commander's Award for Public Service, the Surgeon General's Exemplary Service Award, and the Magnolia Award from the City of Shanghai, China. Dr. Howe is a published author of numerous articles, chapters and abstracts in medical journals, including the New England Journal of Medicine and the Annals of Internal Medicine, among others. Dr. Howe holds a Bachelor of Arts from Amherst College and an M.D. from Boston University School of Medicine. We believe that Dr. Howe is qualified to serve on the Board due to his experience with global medicine and as a leader of international health initiatives.

There are no family relationships among any of our directors or executive officers.

Board Composition

In accordance with the terms of our certificate of incorporation and by-laws, our Board is divided into three classes, with each class having as near an equal number of directors as possible. The terms of service of the three classes are staggered so the term of one class of our Board expires each year. Upon the expiration of the term of a class of directors, directors in that class are eligible to be elected for a new three-year term at the Annual Meeting of stockholders in the year in which their term expires. Our Board currently consists of eight members, divided into three classes as follows:

•: class I consists of Dr. Howe and Mr. Kozin, each with a term expiring at the 2019 annual meeting of stockholders;
•: class II consists of Mr. Aldrich, Ms. Fisher and Dr. Sexton, each with a term expiring at the 2017 annual meeting of stockholders; and
•: class III consists of Dr. Dipp and Messrs. Capello and Malley, each with a term expiring at the 2018 annual meeting of stockholders.

Our certificate of incorporation and by-laws provide that the authorized number of directors may be changed only by resolution of our Board. Our certificate of incorporation and by-laws also provide that our directors may be removed only for cause and only by the affirmative vote of the holders of at least 75% of the votes that all of our stockholders would be entitled to cast in an annual election of

Table of Contents

directors, and that any vacancy on our Board, including a vacancy resulting from an enlargement of our Board, may be filled only by vote of a majority of our directors then in office.

Board Determination of Independence

We determine whether our board members and committee members are independent according to the standards set forth in the Nasdaq Listing Rules. The Nasdaq Listing Rules require that, subject to specified exceptions, each member of a listed company's Audit, Compensation and Nominating and Corporate Governance Committees be independent and that Audit Committee members also satisfy independence criteria set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended. Under Nasdaq Listing Rule 5605(a)(2), a director will only qualify as an "independent director" if, in the opinion of our Board, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule 10A-3, a member of an Audit Committee of a listed company may not, other than in his or her capacity as a member of the Audit Committee, the Board, or any other board committee: (1) accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries; or (2) be an affiliated person of the listed company or any of its subsidiaries.

Based upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our Board determined that none of Messrs. Aldrich, Capello, Kozin, and Malley, Drs. Sexton and Howe, and Ms. Fisher has a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is "independent" as that term is defined under Rule 5605(a)(2) of the Nasdaq Listing Rules. In making its determination, our Board considered the relationships that each such non-employee director has with our company, their beneficial ownership of our outstanding capital stock and all other facts and circumstances our Board deemed relevant in determining their independence. In addition, our Board determined that all of the members of our board's three standing committees described below are independent, as defined under applicable Nasdaq Listing Rules and, in the case of all members of our Audit Committee, the independence requirements contemplated by Rule 10A-3 under the Securities Exchange Act of 1934, as amended.

Board Leadership Structure

Effective as of January 6, 2016, Dr. Dipp became the Executive Chair of the Board, replacing Richard Aldrich, who resigned as Chairman of the Board but continues to serve as a director. In March 2016, Mr. Aldrich was appointed as Independent Lead Director of the Board by the independent directors.

Dr. Dipp's duties as Executive Chair of the Board include the following:

•: preparing or approving the agenda for each board meeting after input from the Board and management; and
•: determining the frequency and length of board meetings and recommending when special meetings of our board should be held; and
•: working to evolve the company's corporate strategy and business development.

Mr. Aldrich's duties as Independent Lead Director include the following:

•: presiding over meetings of the independent directors in executive session;
•: facilitating communications between other members of the Board, the Executive Chair and/or the Chief Executive Officer (when such office is filled); however, each director is free to communicate directly with the Executive Chair and the Chief Executive Officer;

Table of Contents

•: meeting with any director who is not adequately performing his or her duties as a member of our board or any committee;
•: monitoring, with the assistance of the company's general counsel or outside legal advisors, communications from stockholders and other interested parties and provide copies or summaries to the other directors as he or she considers appropriate;
•: reviewing and, if appropriate, recommending action to be taken with respect to written communications from stockholders submitted to our board (see "Board Processes—Communications with Stockholders" below);
•: otherwise consulting with the Executive Chair and/or the Chief Executive Officer on matters relating to corporate governance and Board performance.

Mr. Aldrich, as Independent Lead Director and chair of the Nominating and Corporate Governance Committee, oversees the maintenance and improvement of governance practices that require and support high levels of performance by members of the Board. Mr. Aldrich's leadership encourages open discussion and deliberation, with a thoughtful evaluation of risk, to support the board's decision-making. Mr. Aldrich's leadership also encourages communication among the directors, and between management and the Board, to facilitate productive working relationships.

In late 2015, our Board decided to separate the roles of Executive Chair and Chief Executive Officer and to have an Independent Lead Director because it believed that leadership structure recognized the independent roles of the Board, the Executive Chair and the Chief Executive Officer and offered the following benefits:

•: increasing the independent oversight of OvaScience and enhancing our board's objective evaluation of our Chief Executive Officer;
•: providing the Chief Executive Officer with an experienced sounding board;
•: providing greater opportunities for communication between stockholders and our board; and
•: enhancing the independent and objective assessment of risk by our Board.

Following the departure of Dr. Harald Stock from his employment as our Chief Executive Officer in December 2016, we have initiated a search for a permanent Chief Executive Officer. Pending the identification, recruitment and retention of such individual, Dr. Dipp is serving as both Executive Chair and principal executive officer.

Board Committees

Our Board has established an Audit Committee, a Compensation Committee, a Nominating and Corporate Governance Committee and a Global Strategy Committee. Each committee operates under a charter that has been approved by our Board. Copies of the committee charters are posted on the Investor Relations section of our website, ir.ovascience.com .

Audit Committee

The responsibilities of the Audit Committee include:

•: appointing, terminating (when necessary), approving the compensation of and assessing the independence of our registered public accounting firm;
•: overseeing the work of our registered public accounting firm, including through the receipt and consideration of reports from such firm;

Table of Contents

•: reviewing and discussing with management and the registered public accounting firm our annual and quarterly financial statements and related disclosures;
•: monitoring our internal control over financial reporting, disclosure controls and procedures and code of business conduct and ethics;
•: overseeing our internal audit function;
•: overseeing our risk assessment and risk management policies;
•: establishing policies and procedures for the receipt and retention of accounting related complaints and concerns;
•: meeting independently with our internal auditing staff, registered public accounting firm and management;
•: reviewing and approving or ratifying any related person transactions; and
•: preparing the Audit Committee report required by SEC rules.

The members of the Audit Committee are Messrs. Capello (Chair) and Malley and Dr. Howe. Our Board has determined that each member of the Audit Committee meets the financial literacy requirement under the applicable Nasdaq Listing Rules and that Mr. Capello is an "Audit Committee financial expert" as defined in Item 407(d)(5) of Regulation S-K. All members of the Audit Committee satisfy the current independence standards promulgated by the SEC and by The Nasdaq Stock Market, as such standards apply specifically to members of Audit Committees. The Audit Committee met 10 times during 2016.

All audit and non-audit services, other than de minimis non-audit services, to be provided to us by our independent registered public accounting firm must be approved in advance by our Audit Committee.

Please also see the report of the Audit Committee set forth elsewhere in this proxy statement.

Compensation Committee

The responsibilities of the Compensation Committee include:

•: annually reviewing and approving corporate goals and objectives relevant to our Chief Executive Officer's compensation;
•: determining our Chief Executive Officer's compensation;
•: reviewing and approving, or making recommendations to our board with respect to, the compensation of our other executive officers;
•: overseeing an evaluation of our senior executives;
•: overseeing and administering our equity incentive plans; and
•: reviewing and making recommendations to our board with respect to director compensation.

The members of the Compensation Committee are Mr. Malley (Chair), Ms. Fisher and Dr. Howe. Each of the members is independent as defined under the Nasdaq Listing Rules applicable to Compensation Committee members. The Compensation Committee met 10 times during 2016.

Compensation Consultant. During fiscal year 2016, Pearl Meyer and Partners LLC, or Pearl Meyer, a national executive compensation consulting firm, served as our independent compensation consultant. At the request of our Compensation Committee, Pearl Meyer was engaged by our management team and reported directly to our Compensation Committee. Pearl Meyer assists the

Table of Contents

Compensation Committee in fulfilling its responsibilities under its charter, including advising on proposed compensation packages for executive officers, defining the appropriate market of the Company's peer companies for executive compensation and practices, benchmarking our executive compensation program against the peer group each year and advising on market practices generally. Pearl Meyer also assists the committee in benchmarking our director compensation program and practices against those of our peers. Pearl Meyer interacts with the Compensation Committee, as needed in connection with advising the Compensation Committee, and Pearl Meyer is included in discussions with management and, when applicable, the Compensation Committee's outside legal counsel on matters being brought to the Compensation Committee for consideration.

Pearl Meyer did not provide any services to the Company other than executive and director compensation consulting services during fiscal year 2016. In compliance with SEC rules and the corporate governance rules of The NASDAQ Stock Market, Pearl Meyer provided the Compensation Committee with a letter addressing each of the six independence factors set forth in those rules. Their responses affirm the independence of Pearl Meyer and the partners, consultants, and employees who service the Compensation Committee on executive compensation matters and governance issues. Additionally, the Compensation Committee has assessed the independence of Pearl Meyer pursuant to SEC rules and concluded that Pearl Meyer's work for the Company does not raise any conflict of interest.

Please also see the report of the Compensation Committee set forth elsewhere in this proxy statement.

Nominating and Corporate Governance Committee

The responsibilities of the Nominating and Corporate Governance Committee include:

•: identifying individuals qualified to become board members;
•: recommending to our board the persons to be nominated for election as directors and to each of the Board's committees;
•: reviewing and making recommendations to the Board with respect to management succession planning;
•: developing and recommending to the Board corporate governance guidelines; and
•: overseeing an annual evaluation of the Board.

The members of the Nominating and Corporate Governance Committee are Messrs. Aldrich (Chair) and Kozin. All members of the Nominating and Corporate Governance Committee qualify as independent under the definition promulgated by The Nasdaq Stock Market.

The Nominating and Corporate Governance Committee met once during 2016.

Global Strategy Committee

In March 2016, our Board established a Global Strategy Committee to support the Board in providing board level global strategic guidance to the Executive Chair and executive management team. The Global Strategy Committee's responsibilities include:

•: advising the Executive Chair and executive management team generally on global strategy, as well as on the development and implementation of the Company's strategic plan; and
•: advising the Executive Chair and executive management team on strategies for approaching international markets, including guidance on cultural, regulatory and government affairs matters.

Table of Contents

Each member of the Global Strategy Committee provides individual guidance to the Executive Chair and/or executive management team that is within such member's specialized area of expertise. The members of the Global Strategy Committee are Drs. Howe and Sexton and Mr. Kozin.

Board Meetings and Attendance

Our Board met seven times during 2016. During 2016, each director attended at least 75% of the aggregate of the number of board meetings and the number of meetings held by all committees on which he or she then served.

Our corporate governance guidelines provide that directors are expected to attend Annual Meetings. All of our directors attended our Annual Meeting of stockholders in 2016.

Compensation Committee Interlocks and Insider Participation

For the fiscal year ended December 31, 2016, our Compensation Committee was comprised of Mr. Malley (Chair), Ms. Fisher and Dr. Howe. No member of our Compensation Committee during the fiscal year ended December 31, 2016 has at any time been an officer or employee of ours. None of our executive officers serves as a member of another entity's board of directors or Compensation Committee that has one or more executive officers serving as a member of our Board or Compensation Committee.

Board Processes

Oversight of Risk

Our Board manages its risk oversight function directly and through its committees. Our management is responsible for risk management on a day to day basis. The role of our board and its committees is to oversee the risk management activities of management. They fulfill this duty by discussing with management the policies and practices utilized by management in assessing and managing risks and providing input on those policies and practices. In general, our board oversees risk management activities relating to business strategy, acquisitions, capital allocation, organizational structure and certain operational risks; our Audit Committee oversees risk management activities related to financial controls and legal and compliance risks; our Compensation Committee oversees risk management activities relating to our compensation policies and practices; and our Nominating and Corporate Governance Committee oversees risk management activities relating to board composition and management succession planning. Each committee reports to our board on a regular basis, including reports with respect to the committee's risk oversight activities as appropriate. In addition, since risk issues often overlap, committees from time to time request that the full board discuss particular risks.

Our Compensation Committee has discussed the concept of risk as it relates to our compensation programs, including our executive compensation program. Our Compensation Committee believes that our compensation programs do not encourage excessive or inappropriate risk taking and that any risks arising from our employee compensation policies and practices are not reasonably likely to have a material adverse effect on our company. Our Compensation Committee believes that any such risks are mitigated by:

•: The balanced mix of pay components including base salary, annual cash bonuses and, for most of our employees, equity awards that vest over multiple years and are intended to motivate employees to take a long-term view of our business; and
•: The structure of our annual cash incentive bonus program, which is based on (i) multiple performance measures to avoid employees placing undue emphasis on any particular performance metric at the expense of other aspects of our business, and (ii) performance targets

Table of Contents

that we believe are somewhat aggressive, yet reasonable, and should not require undue risk-taking to achieve.

Director Nomination Process

The process followed by our Nominating and Corporate Governance Committee to identify and evaluate director candidates may include requests to board members and others for recommendations, evaluation of the performance on our board and its committees of any existing directors being considered for nomination, consideration of biographical information and background material relating to potential candidates and, particularly in the case of potential candidates that are not then serving on our board, interviews of selected candidates by members of the committee and our board.

In considering whether to recommend any particular candidate for nomination as a director, our Nominating and Corporate Governance Committee applies the criteria set forth in our Corporate Governance Guidelines. Consistent with these criteria, our Nominating and Corporate Governance Committee expects every nominee to have the following attributes or characteristics, among others: integrity, honesty, adherence to high ethical standards, business acumen, good judgment, and a commitment to understanding our business and industry.

Our directors' biographies, including those of the nominees for director, are contained under "Corporate Governance—Our Board of Directors" and indicate the experience, qualifications, attributes and skills of each of our current nominees for director that led our Nominating and Corporate Governance Committee and our Board to conclude that each of the nominees should continue to serve as a director of OvaScience. Our Nominating and Corporate Governance Committee and our Board believe that each of the nominees has the individual attributes and characteristics required of each of our directors, and the nominees as a group possess the skill sets and specific experience desired of our Board as a whole.

Our Nominating and Corporate Governance Committee does not have a policy (formal or informal) with respect to diversity, but believes that our board, taken as a whole, should embody a diverse set of skills, experiences and backgrounds and consequently considers the value of diversity when selecting nominees. The Nominating and Corporate Governance Committee does not make any particular weighting of diversity or any other characteristic in evaluating nominees and directors.

Stockholders may recommend individuals for consideration as potential director candidates by submitting their names, together with appropriate biographical information and background materials, and information with respect to the stockholder or group of stockholders making the recommendation, including the number of shares of common stock owned by such stockholder or group of stockholders, to OvaScience, Inc., 9 Fourth Avenue, Waltham, Massachusetts 02451, Attention: Nominating and Corporate Governance Committee. The specific requirements for the information that is required to be provided for such recommendations to be considered are specified in our by-laws. Assuming that appropriate biographical and background material has been provided on a timely basis, the Nominating and Corporate Governance Committee will evaluate stockholder-recommended candidates by following substantially the same process, and applying substantially the same criteria, as it follows for candidates submitted by others.

Communications with Stockholders

Our Board will give appropriate attention to written communications that are submitted by stockholders, and will respond if and as appropriate. Stockholders may communicate with the Company through its Investor Relations Department by writing to OvaScience, Inc., 9 Fourth Avenue, Waltham, Massachusetts 02451, Attention: Investor Relations, by calling Investor Relations at 617-500-2802, or by sending an e-mail to info@ovascience.com . Additional information about contacting OvaScience is available on the Investor Relations section of our website, which is located at ir.ovascience.com .

Table of Contents

Stockholders and other persons interested in communicating directly with the Independent Lead Director of the Board or with the non-management directors as a group may do so by writing to OvaScience, Inc., 9 Fourth Avenue, Waltham, Massachusetts 02451, Attn: Independent Lead Director of the Board.

Executive Officers

The following table sets forth certain information regarding our executive officers as of April 1, 2017. The following executive officers are at-will employees.

Name		Position

Michelle Dipp, M.D., Ph.D.	40	Executive Chair
Christophe Couturier, M.B.A.	51	Chief Financial Officer

Michelle Dipp, M.D., Ph.D. Dr. Dipp's biographical information is set forth above under "Our Board of Directors."

Christophe Couturier, M.B.A. has served as our Chief Financial Officer since September 2016. Previously, Mr. Couturier served in various roles with Merck KGaA (Darmstadt, Germany), a global science and technology company in healthcare, life science and performance materials. Most recently, he was Senior Vice President and General Manager at Merck KGaA, where he led the Merck KGaA/Pfizer Global Immuno-Oncology Alliance. From September 2014 to March 2016, he was Senior Vice President of the Merck—KGaA/Sigma-Aldrich Integration Program. From January 2014 through September 2014, he served as Senior Vice President—Head of Bioscience Business. From January 2011 through December 2013, he was Vice President-Head of Services—Process Solutions Business. From April 2010 to January 2011, he was Vice President at the Merck KGaA/Millipore Integration Office. Between 2004 and 2010, Mr. Couturier served in multiple roles, including as the Vice President of Corporate Financial Planning and Analysis and Vice President of Finance Operations in the Bioprocess and BioScience divisions. Prior to joining Merck KGaA in 2004, Mr. Couturier worked as an Associate Partner at IBM Business Consulting Services, as a Finance Director at Lloyds Pharmacy and as a Head of Finance for Novartis, with positions in Hungary, Norway, Turkey and Switzerland. Mr. Couturier received a Baccalaureate, Serie C from Lycee Marcellin Berthelot and an MBA from ESSEC Business School, both in France.

Table of Contents

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

Policies and Procedures for Related Person Transactions

Our Board has adopted written policies and procedures for the review of any transaction, arrangement or relationship in which we are a participant, the amount involved exceeds $120,000, and one of our executive officers, directors, director nominees or 5% stockholders (or their immediate family members), each of whom we refer to as a related person, has a direct or indirect material interest.

If a related person proposes to enter into such a transaction, arrangement or relationship, which we refer to as a "related person transaction," the related person must report the proposed related person transaction to our Chief Legal Officer or, in the event we do not have a Chief Legal Officer, to our Principal Financial Officer. The policy calls for the proposed related person transaction to be reviewed and, if deemed appropriate, approved by the Audit Committee of our Board. Whenever practicable, the reporting, review and approval will occur prior to entry into the transaction. If advance review and approval is not practicable, the committee will review, and, in its discretion, may ratify the related person transaction. The policy also permits the chair of the committee to review and, if deemed appropriate, approve proposed related person transactions that arise between committee meetings, subject to ratification by the committee at its next meeting. Any related person transactions that are ongoing in nature will be reviewed annually.

A related person transaction reviewed under the policy will be considered approved or ratified if it is authorized by the committee after full disclosure of the related person's interest in the transaction. As appropriate for the circumstances, the committee will review and consider:

•: the related person's interest in the related person transaction;
•: the approximate dollar value of the amount involved in the related person transaction;
•: the approximate dollar value of the amount of the related person's interest in the transaction without regard to the amount of any profit or loss;
•: whether the transaction was undertaken in the ordinary course of our business;
•: whether the terms of the transaction are no less favorable to us than terms that could have been reached with an unrelated third party;
•: the purpose of, and the potential benefits to us of, the transaction; and
•: any other information regarding the related person transaction or the related person in the context of the proposed transaction that would be material to investors in light of the circumstances of the particular transaction.

The committee may approve or ratify the transaction only if the committee determines that, under all of the circumstances, the transaction is not inconsistent with our best interests. The committee may impose any conditions on the related person transaction that it deems appropriate.

In addition to the transactions that are excluded by the instructions to the SEC's related person transaction disclosure rule, our Board has determined that the following transactions do not create a direct or indirect material interest on behalf of related persons and, therefore, are not related person transactions for purposes of this policy:

•: interests arising solely from the related person's position as an executive officer of another entity (whether or not the person is also a director of such entity), that is a participant in the transaction, where (a) the related person and all other related persons own in the aggregate less than a 10% equity interest in such entity, (b) the related person and his or her immediate family members are not involved in the negotiation of the terms of the transaction and do not receive

Table of Contents

any special benefits as a result of the transaction and (c) the amount involved in the transaction equals less than the greater of $200,000 or 5% of the annual consolidated gross revenues of the other entity that is a party to the transaction; and

•: a transaction that is specifically contemplated by provisions of our charter or by-laws.

The policy provides that transactions involving compensation of executive officers shall be reviewed and approved by the Compensation Committee in the manner specified in its charter.

Related Person Transactions

Except as set forth below and in this proxy statement under the captions "Executive Compensation" and "Director Compensation," there were no transactions to which we were a party since January 1, 2016 through the date of this proxy statement with our directors and officers and beneficial owners of more than 5% of our voting securities and their affiliates.

Public Offerings of Common Stock

In June 2016, we issued and sold an aggregate of 8,222,500 shares of common stock at a price per share of $7.00, pursuant to a shelf registration statement on Form S-3, for an aggregate purchase price of approximately $53.9 million. The following table sets forth the number of shares of our common stock that we issued to our directors, executive officers, 5% stockholders and their affiliates in this registered offering:

Name		Shares of Common Stock

Longwood Fund, LP(1)			425,000

(1): Richard Aldrich and Michelle Dipp, M.D., Ph.D., members of our board of directors and holders of more than 5% of our voting securities, are members of the general partner of Longwood Fund, LP.

Equity Awards

On January 5, 2017, our Board of Directors approved an equity grant to Christophe Couturier, our Chief Financial Officer in the amount of 100,000 stock options with a grant date fair value of $124,655. The options vest in equal quarterly amounts over two years following the grant date.

On March 3, 2017, our Board of Directors approved an additional equity grant to Mr. Couturier in the amount of 45,750 stock options with a grant date fair value of $51,892 and an equity grant to Dr. Dipp in the amount of 150,000 stock options with a grant date fair value of $170,139. The options vest as to 25% of the option shares on March 2, 2018 and as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter until March 2, 2021.

Indemnification

Our certificate of incorporation provides that we must indemnify our directors and officers to the fullest extent permitted by Delaware law and must advance expenses, including attorneys' fees, to our directors and officers in connection with legal proceedings, subject to very limited exceptions. In addition, we have entered into indemnification agreements with our directors.

Table of Contents

COMPENSATION DISCUSSION AND ANALYSIS

Our Compensation Committee is responsible for overseeing the total compensation of our executive officers. In this capacity, our Compensation Committee designs, implements, reviews and approves all compensation for our Chief Executive Officer and our other Named Executive Officers. This section discusses the principles underlying our policies and decisions with respect to the compensation of our executive officers who are named in the Summary Compensation Table below, or our Named Executive Officers, and all material factors relevant to an analysis of these policies and decisions. Our Named Executive Officers for purposes of this disclosure are:

•: Michelle Dipp, M.D., Ph.D., our Executive Chair;
•: Christophe Couturier, our Chief Financial Officer;
•: Harald Stock, Ph.D., our former Chief Executive Officer;
•: Jeffrey E. Young, our former Chief Financial Officer;
•: Paul Chapman, our former Chief Operating Officer; and
•: Arthur Tzianabos, Ph.D., our former President and Chief Scientific Officer.

Executive Summary and Corporate Background

We are a global fertility company focused on the discovery, development, and commercialization of new fertility treatment options for women. 2016 was a year of significant developments in our business and strategy, as well as transitions in our executive management team.

•: On January 6, 2016, we announced that Dr. Stock, who was then a member of our Board, had been appointed as our Chief Executive Officer-Elect, and would begin to serve as our Chief Executive Officer on July 1, 2016, and that Dr. Dipp would remain as Chief Executive Officer until July 1, 2016. On January 6, 2016, Dr. Dipp also became our Executive Chair of the Board.
•: Mr. Chapman joined our management team in February 2016 as Chief Operating Officer.
•: During 2016, we continued to make progress on our development and business goals, including the expansion of our global sales and marketing team in anticipation of the commercial launch of our AUGMENT ^SM treatment in regions outside of the United States. We also continued to drive the development of our OvaPrime ^SM and OvaTure ^SM treatments, with a focus on expanding in key strategic regions such as Japan, Western Europe and Canada.
•: In December 2016, we determined to change our corporate strategy. As part of this strategic shift, we announced that we would continue to make AUGMENT ^SM available to patients at partner clinics in Canada and Japan and maintain our current commercial footprint, but would slow our commercial expansion, reassess the ongoing and planned clinical studies of AUGMENT, and undertake a corporate restructuring, including a workforce reduction to better align our workforce to our revised corporate strategy and to carefully manage our cash burn. These changes will enable us to extend our cash position into the first quarter of 2019 and increase our focus on the development of OvaPrime and OvaTure.
•: In January 2017, following the announcement of the restructuring, we approved a retention plan providing for cash bonuses and equity grants for participating employees, including our Chief Financial Officer, Mr. Couturier. The purpose of the retention plan is to incentivize employees to remain with us following the announcement of the corporate restructuring. Pursuant to the retention plan, participating employees will receive equity grants that vest over a two year period and cash bonuses, payable either in a lump sum or over time, subject to the employees' remaining with us as of the vesting or payment dates.

Table of Contents

•: In connection with our change in corporate strategy, Dr. Stock and Mr. Chapman left their employment with us in December 2016. Dr. Dipp will continue to serve as Executive Chair and will serve as acting President and principal executive officer while the Company conducts a search for a new Chief Executive Officer. That search is ongoing.
•: In September 2016, Mr. Couturier joined our management team as Chief Financial Officer, and Mr. Young left the company to pursue other opportunities.
•: Dr. Tzianabos left employment with us on March 31, 2016.

The goal of our Compensation Committee is to ensure that our compensation programs are aligned with the interests of our stockholders and our business goals and that the total compensation paid to each of our Named Executive Officers is fair, reasonable and competitive. Key elements of our compensation programs include:

•: cash compensation, including base salary and annual bonuses, to enable us to attract and retain the talent needed to continue to drive our business successfully; and
•: equity incentive compensation, which is provided to all employees, is typically subject to multi-year vesting based on continued service and is primarily in the form of stock options, the value of which depends on the performance of our common stock price, or restricted stock units, in order to align employee interests with those of our stockholders over the longer-term.

We target competitive pay opportunities as compared to similarly situated executives of the companies in our peer group for total cash compensation and total equity compensation. Actual compensation levels are correlated to the achievement of corporate and individual goals, reinforcing our pay-for-performance philosophy. In addition, we adhere to market best practices in administering our executive compensation program:

What We Do

What We Don't Do

✓

Consult with an independent compensation consultant

✓

Conduct an annual review of pay levels

✓

Incentive payouts based on multiple performance measures

✓

Multi-year vesting of equity awards

✗

No tax gross-up payments to our executive team for any change-of-control payments

✗

No hedging transactions with our securities or pledging our securities

✗

No excessive benefits or perquisites

✗

No option repricing without shareholder approval

Based on our performance during 2016, our Compensation Committee determined that we achieved 61% of our corporate goals for 2016. In 2016, payouts under our bonus program depended on our executives meeting certain targets in the areas of commercial and clinical developments with respect to AUGMENT, decisions and development milestones with respect to the OvaPrime and OvaTure programs, and financial metrics, each to advance the Company's strategic growth plan.

Defining and Comparing Compensation to Market Benchmarks

In evaluating the total compensation of our Named Executive Officers, our Compensation Committee, using information provided by Pearl Meyer, establishes a peer group of publicly traded, national and regional companies in the life sciences industry that is selected based on a balance of the following criteria:

•: companies whose number of employees and stage of development are similar, though not necessarily identical, to ours;

Table of Contents

•: companies against which we believe we compete for executive talent; and
•: public companies based in the United States whose compensation and financial data are available in various filings with the Securities and Exchange Commission or through widely available compensation surveys.

Based on these criteria, our Compensation Committee established and approved a peer group in November 2015 to determine pay levels for 2016, which was comprised of the following companies:

•: Acceleron Pharma, Inc.
•: Aegerion Pharmaceuticals, Inc.
•: Cempra, Inc.
•: ChemoCentryx, Inc.
•: Foundation Medicine, Inc.
•: Karyopharm Therapeutics, Inc.
•: NanoString Technologies, Inc.
•: Relypsa, Inc.
•: Revance Therapeutics, Inc.
•: Sage Therapeutics, Inc.
•: Sarepta Therapeutics, Inc.
•: Tesaro, Inc.
•: Tetraphase Pharmaceuticals, Inc.
•: TherapeuticsMD, Inc.
•: Zafgen, Inc.
•: ZS Pharma, Inc.

We believe that the compensation practices of our peer group provided us with appropriate compensation benchmarks for evaluating the compensation of our Named Executive Officers during 2016. Notwithstanding the similarities of the peer group to OvaScience, due to the nature of our business, we compete for executive talent with many public companies that are larger and more established than we are or that possess greater resources than we do, or with smaller private companies that may be able to offer greater equity compensation potential, as well as with prestigious academic and non-profit institutions. Accordingly, in 2016, our Compensation Committee generally targeted competitive compensation levels compared to our peer group with respect to base salaries, annual cash bonus opportunities, annual equity incentive awards and overall compensation for our Named Executive Officers. While our peer group is used to identify competitive market rates, our Compensation Committee also considers other criteria, including market factors, the experience level of the executive and the executive's performance against established corporate goals, in determining variations to this general target range.

Following the change in our corporate strategy noted above, our Compensation Committee intends to select a new peer group for use in evaluating compensation of our Named Executive Officers. That new peer group has not yet been selected, but we anticipate that it will reflect our new corporate focus and be comprised of similarly situated companies.

Table of Contents

Compensation Principles and Objectives

Our overall compensation program is structured to attract, motivate and retain highly qualified executive officers by paying them competitively, consistent with our success and their contribution to that success. Our ability to excel depends on the skill, creativity, integrity and teamwork of our employees. We believe compensation should be structured to ensure that a portion of compensation opportunity will be related to factors that directly and indirectly influence long-term stockholder value. Our compensation philosophy has been driven by a number of factors that are closely linked with our broader strategic objectives.

The Compensation Committee believes that compensation paid to our Named Executive Officers should be aligned with our performance on both a short-term and long-term basis, linked to results intended to create value for stockholders, and that such compensation should assist us in attracting and retaining key executives critical to our long-term success.

In establishing compensation for executive officers, the following are the Compensation Committee's objectives:

•: align executive officer and stockholder interests by providing a portion of total compensation opportunities for executives in the form of equity awards and bonuses awarded based on the Compensation Committee's review of company and individual performance;
•: ensure executive officer compensation is competitive within the marketplace in which we compete for executive talent by relying on the Compensation Committee's judgment, expertise and personal experience with other similar companies, recognizing that because of the company's business model and relatively early stage of development, there may be few directly comparable companies; and
•: recognize that best compensation practices for a growing young company may be substantially different than for a larger, more mature company and that we should make full use of our greater latitude and breadth of compensation opportunities.

Determination of Compensation

The Compensation Committee is charged with the primary authority to determine and recommend the compensation awards available to our executive officers for approval by the Board. Based on the Compensation Committee members' collective understanding of compensation practices in similar companies in the biotechnology and pharmaceutical industry, our executive compensation package consists of the following elements, in addition to the employee benefit plans in which all employees may participate:

•: Base salary: cash compensation for ongoing services throughout the year.
•: Annual cash bonus awards: cash awards to recognize and reward achievement of corporate and individual performance.
•: Long-term equity incentive program: equity compensation to provide an incentive to our Named Executive Officers to manage us from the perspective of an owner with an equity stake in the business.
•: Severance and change in control benefits: remuneration paid to certain executives in the event of a qualifying termination of employment.

We set base salary and annual bonus structures and any grants of equity awards based on the Compensation Committee members' collective understanding of compensation practices in the biotechnology industry and such members' experiences as seasoned executives, consultants, board and Compensation Committee members, or investors in similar biotechnology and specialty pharmaceutical industry companies. In addition, from time to time the Compensation Committee may rely on compensation data provided by Pearl Meyer.

Table of Contents

Annual Performance Reviews

As part of its role, the Compensation Committee has adopted a process under which annual performance goals are determined by the Chief Executive Officer and set forth in writing at the beginning of each calendar year for the corporation as a whole and each individual executive. Annual corporate goals are proposed by our management team and approved by our Board in the first quarter of each fiscal year. These corporate goals target the achievement of specific operational milestones. The Chief Executive Officer's goals are tied to the annual corporate goals and are approved by the Compensation Committee of the Board. The annual individual goals of the other executives are determined by the Chief Executive Officer and focus on contributions which facilitate the achievement of specific corporate goals and are set during the first quarter of each calendar year. Annual bonuses are tied to the achievement of the corporate goals, and each individual's contribution to the achievement of specific corporate goals.

Our Compensation Committee conducts an annual performance review of our Named Executive Officers and approves the compensation of each member of our senior management team. By the first quarter of each year, annual corporate goals and individual performance objectives are determined and set forth in writing. After the end of each year, our Compensation Committee determines executive compensation levels after carefully reviewing overall corporate performance and performing an evaluation of each Named Executive Officer's annual performance against established corporate goals, as well as each individual executive officer's contributions to achievement of the corporate goals and, in the case of executive officers other than our Chief Executive Officer, the achievement of individual performance objectives. In addition, our Compensation Committee may apply its discretion, as it deems appropriate, in determining executive compensation.

For 2016, our Executive Chair's bonus was based entirely on performance relative to corporate goals and the bonuses of our other Named Executive Officers were based on a combination of corporate goals and individual objectives. Individual objectives for 2016 for our executive officers focused on individual contributions that were intended to drive achievement of the corporate goals, including targets in the areas of commercial and clinical developments with respect to AUGMENT, decisions and development milestones with respect to the OvaPrime and OvaTure programs, and financial metrics, each to advance the Company's strategic growth plan. Any cash awards were based on the achievement of these corporate and individual performance goals and objectives.

Elements of Executive Compensation

Base Salaries

Base salaries of our Named Executive Officers (other than our Executive Chair) are recommended and reviewed periodically by our Executive Chair, and, after recommendation from the Executive Chair to the Compensation Committee, the base salary for each Named Executive Officer is approved by our Compensation Committee. The compensation of our Executive Chair is set by the Compensation Committee. Adjustments to base salaries are based on the scope of an executive's responsibilities, individual contribution, experience and sustained performance. Decisions regarding salary increases may also take into account amounts paid to individuals in comparable positions at our peer companies. No formulaic base salary increases are provided to our Named Executive Officers. This strategy is consistent with our intent of offering compensation that is cost-effective, competitive and contingent on the achievement of performance objectives.

Dr. Dipp is a founder of our company. As such, from the time the company was founded in 2011 until Dr. Dipp's appointment to the role of Executive Chair in January 2016, we did not compensate Dr. Dipp with cash for her service. In lieu of cash compensation, Dr. Dipp received time-based restricted stock unit awards and stock options until her appointment as Executive Chair in 2016, at which time we entered into a five year employment agreement, or the EC Agreement, with Dr. Dipp.

Table of Contents

Pursuant to the EC Agreement, Dr. Dipp will initially receive an annual base salary of $500,000 per year, and is eligible for a cash bonus, as described below. The EC Agreement will expire on December 31, 2020, unless earlier terminated in accordance with its terms. Pursuant to the EC Agreement, Dr. Dipp's currently outstanding options to purchase common stock will continue to vest pursuant to their current vesting schedule while she serves as Executive Chair. The unvested portion of Dr. Dipp's time-based restricted stock unit award (in the amount of 15,451 restricted stock units) issued in December 2014 was terminated upon entry into the EC Agreement. Dr. Dipp did not receive any new equity grant in connection with entering the EC Agreement.

Mr. Couturier, Dr. Stock, Dr. Tzianabos, Mr. Young and Mr. Chapman joined us after we were founded, and their initial compensation was the result of arms-length negotiations at the time each employee began employment.

In connection with Dr. Stock's joining the Company in January 2016, his annual base salary was set at $650,000, with an increase to $700,000 planned to take effect on January 1, 2017. Dr. Stock also received a sign-on bonus of $200,000. This was determined through negotiations with the Company and was determined to be in line with chief executive officer compensation for similarly situated companies, in particular, companies that were focused on commercializing products and no longer purely or primarily in the development stage of their businesses. The Company also paid for or reimbursed Dr. Stock for reasonable costs and expenses related to his relocation from Germany and provided him with a net housing allowance of $6,000 per month.

In connection with Mr. Chapman's joining the Company in February 2016, his annual base salary was set at $425,000. This was determined through negotiations with the Company and was determined to be in line with chief operating officer compensation for similarly situated companies. We also agreed to pay Mr. Chapman a retention bonus of up to $100,000, payable in equal quarterly installments at the end of each quarter of fiscal year 2016, provided that Mr. Chapman was employed by us on each payment date. He received $75,000 pursuant to this arrangement prior to his departure from the Company in December 2016.

In connection with Mr. Couturier's joining the Company in September 2016, his annual base salary was set at $400,000. This was determined through negotiations with the Company and was determined to be in line with chief financial officer compensation for similarly situated companies.

In connection with Mr. Young's joining the Company in July 2014, his annual base salary was set at $315,000. In December 2015, Mr. Young's base salary was increased to $380,000, effective December 1, 2015. As noted above, Mr. Young left the Company in September 2016.

The actual base salaries paid to all of our Named Executive Officers during 2016 are set forth in the "Summary Compensation Table" below.

Annual Bonuses

As described above, until January 2016, Dr. Dipp had not historically received cash compensation, including any cash bonus. Instead, in December 2014, Dr. Dipp received performance-based restricted stock unit awards representing the right to receive a target amount of 15,451 shares of common stock, or 50% of her time-based restricted stock units, which were scheduled to vest annually over a two year period upon meeting certain performance-based vesting conditions, provided that Dr. Dipp could have earned up to 150% of such target amount (or a maximum of 23,176 shares) based upon surpassing such performance-based conditions. As noted above, the unvested portions of these performance-based restricted stock unit awards (or 18,541 shares) have been terminated in connection with the entry into the EC Agreement.

Cash bonuses are intended to provide incentives to drive company-wide performance. Our Named Executive Officers are eligible to receive an annual cash bonus targeted as a percentage of the

Table of Contents

executive's base salary. Pursuant to the EC Agreement, Dr. Dipp may be awarded an annual target bonus of up to 60% of her then-current annual base salary, provided that the annual bonus may equal up to 90% of her then-current base salary if Dr. Dipp achieves over 100% of her performance objectives. Mr. Couturier is eligible to receive an annual discretionary target bonus of up to fifty percent (50%) of his annual salary, provided that he may receive as much as 150% of his target bonus if he exceeds his performance objectives. The bonus awards, if any, will be determined by the Board, or a committee thereof in its sole discretion, based on the achievement of performance objectives.

Prior to their departures from the Company, each of Dr. Stock, Dr. Tzianabos, Mr. Chapman and Mr. Young had target cash bonus amounts, as follows:

•: Dr. Stock was eligible to be awarded an annual target bonus of up to 60% of his then-current annual base salary, provided that the annual bonus award could equal 90% of his then-current base salary if Dr. Stock's performance objective achievement was 120% or higher.
•: Mr. Chapman was eligible to be awarded an annual bonus of 50% of his annual salary.
•: Mr. Young was eligible to be awarded an annual bonus of 50% of his annual salary.
•: Dr. Tzianabos was eligible to be awarded an annual bonus of 50% of his annual salary.

The bonus awards for these executives, if any, were to be determined by the Company's Board of Directors or a committee thereof and would have been based upon the achievement of specific individual and corporate goals, as determined by the Board of Directors or a committee thereof. However, because each of these individuals had departed the Company prior to the determination of bonus achievements for 2016, no bonuses were awarded to any of these individuals, other than Mr. Young, who received a partial bonus in recognition of his past contributions to the Company.

Under the 2016 annual bonus program, bonus awards were determined by first establishing a bonus pool. The bonus pool was calculated by aggregating the maximum awards for all eligible plan participants and then multiplying that sum by a modifier established by our Compensation Committee based on our performance as measured against the 2016 corporate goals. The bonus pool was then allocated among all of the plan participants in accordance with the terms of the 2016 annual bonus program.

The determination of the amount of annual bonuses paid to our Named Executive Officers generally reflects a number of considerations by the Compensation Committee acting in their discretion, including, among other things, the performance of the company and a subjective evaluation of the individual contribution and performance of each Named Executive Officer. Bonus determinations are not formulaic and no particular weight is assigned to any of the factors considered by the Compensation Committee.

The table below shows the target award under the 2016 annual bonus program as a percentage of each Named Executive Officer's annual base salary in 2016, the target cash award opportunity in dollars for 2016 and the actual cash bonus payments to our Named Executive Officers for 2016 performance, which were paid in March 2017, as well as the actual bonus payment as a percentage of the target award opportunity. The details regarding the determination of these cash bonus awards are discussed below.

2016 Annual Bonus Program

Name	2016 Target Award (% of Base Salary)		2016 Target Award Opportunity ($)		2016 Actual Bonus Payment ($)		2016 Actual Bonus Payment (% of Target Award Opportunity)
Michelle Dipp, M.D., Ph.D.		60		300,000		183,000		61
Christophe Couturier		50		200,000		134,200		67

Table of Contents

In making its determinations regarding awards under the 2016 annual bonus program, our Compensation Committee considered our success against our 2016 corporate goals. The 2016 corporate goals approved by our board, the relative weightings assigned to each goal at the beginning of the year, and our actual achievement during the performance period as a percentage of target and the weighted performance against these corporate goals for 2016, were as follows:

2016 Corporate Goals

•	AUGMENT
	•	Targeted growth in commercial AUGMENT sales	28	%	0	%	0	%
	•	Progress in entering into commercial agreements with new clinics	14	%	90	%	12	%
	•	Progress on IVI study	14	%	100	%	14	%
•	Resolve go/no go decision for OvaPrime program		20	%	100	%	20	%
•	Advance OvaTure development by obtaining authorization to fertilize and characterize an EggPC-derived egg and embryo and defining clinical path forward		15	%	33	%	5	%
•	Manage actual quarterly expenses and successfully manage long-term cash runway		10	%	100	%	10	%
	Approved 2016 Corporate Performance Level		100	%			61	%

During 2016, we made progress on our business goals, including:

•: We received IRB approval to begin an OvaPrime clinical trial in Canada, and have since begun enrolling and treating patients in our OvaPrime clinical trial, titled "A Single Center, Prospective, Controlled Pilot Study of OvaPrime Procedure," which is being performed to evaluate the safety of the OvaPrime procedure in subjects with poor ovarian response or diminished ovarian response.
•: We made the decision to move the OvaTure program forward. In December 2013, we entered into a collaboration with Intrexon, a leader in synthetic biology, to accelerate development of OvaTure, which we refer to as the OvaTure Collaboration. The companies also formed OvaXon LLC, a joint venture designed to develop applications to prevent inherited human diseases and improve animal health. In 2016, the OvaTure Collaboration and OvaXon generated data supporting the characterization and developmental competence of human and bovine EggPC cell derived-eggs, respectively.
•: We expanded the availability of the AUGMENT treatment in select international regions, and scheduled a meeting with the FDA in the first half of 2017 to explore potential entry into the U.S. market. We have since decided that while we would continue to make AUGMENT available to patients at partner clinics in Canada and Japan and maintain our current commercial footprint, we would slow our commercial expansion, reassess the ongoing and planned clinical studies of AUGMENT, and undertake a corporate restructuring.

On January 5, 2017, the Compensation Committee determined that the Company had achieved 61% of its corporate goals, as set forth above. Individual objectives for 2016 for our executive officers focused on individual contributions that were intended to drive overall achievement of the corporate goals. Dr. Dipp had individual goals weighted towards treatment development and expansion of the company's business. Mr. Couturier had individual goals weighted towards finance goals and management of expenses and the Compensation Committee determined that he had exceeded those goals, resulting in a goal achievement percentage of 67%.

Table of Contents

Equity Awards

We have historically not granted short-term, equity-based incentive awards. The goals of our long-term, equity-based incentive awards are to align the interests of our Named Executive Officers with the interests of our stockholders. Because vesting is based on continued service, rather than achievement of performance objectives, our equity-based incentives also encourage the retention of our Named Executive Officers during the award vesting period. In determining the size of the long-term equity incentives to be awarded to our Named Executive Officers, we take into account a number of factors, such as the relative job scope, the value of existing stockholdings and long-term incentive awards, individual performance history, prior contributions to our business and the size of prior grants.

To reward and retain our Named Executive Officers in a manner that aligns their interests with stockholders' interests, we have historically used stock options as the primary incentive vehicle for long-term compensation. Because employees realize value from stock options only if our stock price increases relative to the stock option's exercise price, we believe stock options provide meaningful incentives to achieve increases in the value of our stock over time.

We have generally used stock options to compensate our Named Executive Officers both in the form of initial grants in connection with the commencement of employment and additional or "refresher" grants, but have also used restricted stock unit awards due to the maturation of the company, volatility in the company's stock price and the fact that certain Named Executive Officers hold stock options that are significantly out-of-the money. While we do review the competitive practices of the companies in our peer group, we have not established a formula or program for determining the size of any equity award, including any annual refresher grants, and our Compensation Committee retains discretion to make stock or option awards to employees at any time, including in connection with the promotion of an employee, to reward an employee, for retention purposes or in other circumstances recommended by management.

The exercise price of each stock option grant is at or above the fair market value of our common stock on the grant date, for which we use the closing price of our common stock on the grant date. Stock option awards typically vest over a four-year period as follows (subject to continued service through the applicable vesting date): 25% of the shares underlying the option vest on the first anniversary of the vesting commencement date, and 6.25% of the shares will vest in equal quarterly installments over the following three years. We believe these vesting schedules appropriately encourage continued service with the company while allowing our executives to realize compensation in line with the value they have created for our stockholders.

On March 2, 2017, the Compensation Committee decided to make stock option grants to each of Dr. Dipp and Mr. Couturier in the amounts of 150,000 shares and 45,750 shares, respectively, in recognition of the contributions to the Company during 2016 of each of these individuals. These options have an exercise price of $1.49 per share.

In connection with the commencement of his employment with us, Mr. Couturier received an option to purchase 200,000 shares of Common Stock, at an exercise price of $7.15 per share. The stock option has a ten-year term, vesting over four years, with 25% of the shares vesting on September 6, 2017 and 6.25% of the shares vesting each quarter thereafter. Mr. Couturier also received a restricted stock unit award representing the right to receive 50,000 shares of Common Stock, which vests over four years, 25% of which will vest on September 6, 2017 and 6.25% of which will vest each quarter thereafter. In the event of a change of control (as defined in Mr. Couturier's employment agreement with the Company, or the "Offer Letter") of the Company where Mr. Couturier's employment is terminated by the Company without cause (as defined in the Offer Letter) or Mr. Couturier resigns for good reason (as defined in the Offer Letter) within one year of the change of control, the vesting of the stock options and restricted stock units will accelerate in full.

Table of Contents

Additionally, Mr. Couturier's offer letter provided that if Mr. Couturier remained employed by the Company as of the first regularly scheduled meeting of the Board of Directors or the Compensation Committee of the Board of Directors in 2017, Mr. Couturier would be eligible to receive, subject to the percentage achievement of performance objectives to be determined by the Compensation Committee or the Board of Directors and approval of such grant by the Compensation Committee or the Board of Directors, an additional grant of up to 75,000 options.

In connection with his appointment as our Chief Executive Officer-Elect, Dr. Stock was granted an option to purchase 250,000 shares of our common stock at an exercise price of $9.42 per share. Dr. Stock also received a restricted stock unit award representing the right to receive 250,000 shares of common stock. None of these options or restricted stock unit awards vested prior to his departure from the Company in December 2016, and all of these unvested options and restricted stock units were forfeited upon his departure.

In connection with his appointment as our Chief Operating Officer, Mr. Chapman was granted an option to purchase 350,000 shares of our common stock, at an exercise price of $6.96 per share. All unvested options were forfeited upon Mr. Chapman's departure from the Company in December 2016.

No other grants were made to any of our Named Executive Officers during 2016.

Retention Agreements

Because of the transitions facing the Company and the Compensation Committee's desire to encourage Dr. Dipp to continue leading the Company until such time as a permanent Chief Executive Officer can be identified and retained, the EC Agreement between the Company and Dr. Dipp includes a retention agreement providing that Dr. Dipp will be entitled to receive $37,500 on the last day of each quarter ending between March 31, 2016 and December 31, 2017 for so long as Dr. Dipp is employed by OvaScience at the end of the applicable quarter.

In light of the corporate restructuring announced in December 2016, and in order to incentivize certain employees to remain with the Company to implement the Company's new strategic direction, at its meeting on January 5, 2017, the Compensation Committee approved a retention plan providing for cash bonuses and equity grants for employees of the Company, including Mr. Couturier. Pursuant to the retention plan, Mr. Couturier received an option to purchase 100,000 shares of Common Stock, vesting in equal quarterly amounts over two years, and a cash bonus totaling $100,000, payable in two tranches of $50,000 each in the first pay periods following June 30, 2017 and December 31, 2017, subject to his remaining with the Company on such dates.

Severance and Change in Control Arrangements

Our Named Executive Officers either have or had employment arrangements that provide that they are eligible to receive severance payments and benefits upon an involuntary termination of employment, whether or not in connection with a change in control of our company. We believe that this protection serves to encourage continued attention and dedication to duties without distraction arising from the possibility of a change in control, and provides the business with a smooth transition in the event of such a termination of employment in connection with a transaction. These severance and change in control arrangement are designed to keep our Named Executive Officers in these key positions as we compete for talented executives in the marketplace where such protections are commonly offered. For a detailed description of the severance provisions contained in our Named Executive Officers' employment arrangements, see "Potential Payments Upon Termination or Change in Control" below.

In connection with the departures from employment with the Company in December 2016 of Dr. Stock and Mr. Chapman, we entered into separation agreements with each individual. Dr. Stock's

Table of Contents

separation agreement provided for a payment of fourteen (14) months of his base salary, which was lower than the eighteen (18) months provided for in his employment agreement in the event of a termination without cause, and the termination of all equity grants. Mr. Chapman's separation agreement provided for a payment of eight (8) months of his base salary and the termination of all equity grants.

On March 31, 2016, Dr. Tzianabos resigned as our President and Chief Scientific Officer to assume the role of Chief Executive Officer at an early stage biotechnology company. We and Dr. Tzianabos entered into a consulting agreement, or the Consulting Agreement, which provided for Dr. Tzianabos to act as an advisor to us through December 31, 2016, to facilitate an orderly transition of his employment duties and responsibilities, meet with and educate third parties about us and our science, and perform special projects as identified by us. We and Dr. Tzianabos also entered into a separation agreement, or the Separation Agreement, pursuant to which he received (i) six months of his then-current annual base salary, paid out pursuant to our normal payroll practices over six months; (ii) continued vesting of his unvested stock option and unvested restricted stock unit awards during the time that he was advising with us; and (iii) extension of the exercise period of all his stock option awards until the later of (a) March 31, 2017 or (b) three months after the termination of the Consulting Agreement. Pursuant to the Consulting Agreement, Dr. Tzianabos received a flat fee of $8,333 per month while he was advising with us.

In connection with Mr. Young's departure from employment with the Company in September 2016, he received a payment of $190,000, representing six months of his base salary as provided for in his offer letter from the Company, and a bonus of $150,000, reflecting his past contributions to the Company and a pro-rated portion of his target 2016 bonus.

If we terminate Dr. Dipp's or Mr. Couturier's employment without cause or Dr. Dipp or Mr. Couturier terminates her or his employment for good reason, she or he will be entitled to receive (a) continuation of her or his then-current base salary for a period of six months (the "Severance Period"), which will be payable in periodic installments over the same period and (b) continuation of COBRA health insurance premiums at the Company's then-normal rate of contribution during the Severance Period.

Tax Considerations

Elimination of 280G Tax Gross Up Provision

Section 280G of the Code disallows a tax deduction with respect to excess parachute payments to certain executives of companies which undergo a change in control. In addition, Section 4999 of the Code imposes a 20% excise tax on the individual with respect to the excess parachute payment. Parachute payments are compensation linked to or triggered by a change in control and may include, but are not limited to, bonus payments, severance payments, certain fringe benefits, and payments and acceleration of vesting from long-term incentive plans including stock options and other equity-based compensation. Excess parachute payments are parachute payments that exceed a threshold determined under Section 280G of the Code based on the executive's prior compensation. In approving the compensation arrangements for our Named Executive Officers in the future, our Compensation Committee will consider all elements of the cost to the company of providing such compensation, including the potential impact of Section 280G of the Code. Dr. Dipp's previous employment agreement, that was entered into in December 2014, provided that a tax gross-up would be paid on Dr. Dipp's behalf if any amounts payable by the company (or a successor) to her became subject to excise taxes under Sections 280G and 4999 of the Internal Revenue Code, the 280G tax gross-up provision. In connection with entering into the EC Agreement, Dr. Dipp agreed to eliminate this 280G tax gross-up provision.

Table of Contents

COMPENSATION COMMITTEE REPORT

The Compensation Committee of our Board has reviewed and discussed the Compensation Discussion and Analysis required by Item 402(b) of Regulation S-K, which appears elsewhere in this proxy statement, with our management. Based on this review and discussion, the Compensation Committee has recommended to the Board that the Compensation Discussion and Analysis be included in our proxy statement.


		Members of the OvaScience, Inc. Compensation Committee Thomas Malley, Chair Mary Fisher John Howe, III, M.D.

Table of Contents

EXECUTIVE COMPENSATION

Overview

For 2016, our "Named Executive Officers" were Michelle Dipp, M.D., Ph.D., our Executive Chair; Christophe Couturier, our Chief Financial Officer; Harald Stock, Ph.D., our former Chief Executive Officer; Jeffrey Young, our former Chief Financial Officer; Arthur Tzianabos, Ph.D., our former President and Chief Scientific Officer; and Paul Chapman, our former Chief Operating Officer.

Summary Compensation Table

The following table sets forth the total compensation awarded to, earned by or paid to our Named Executive Officers during 2014, 2015 and 2016:

Name and Principal Position

Michelle Dipp, M.D., Ph.D.	2016	478,846	333,000	(2)	—		—	18,566	(3)	830,412
Executive Chair	2015	—	—		435,794	(4)(5)(6)	—	—		435,794
	2014	—	—		1,280,444	(4)(7)	4,348,586	—		5,629,030
Christophe Couturier	2016	113,846	139,200	(8)	357,500	(9)	1,035,052	7,014	(10)	1,652,612
Chief Financial Officer
Harald Stock, Ph.D.(11).	2016	627,446	200,000	(12)	2,355,000	(7)	1,611,388	952,384	(13)	5,746,218
Former Chief Executive Officer
Arthur Tzianabos, Ph.D.(14)	2016	120,962	—		—		—	328,916	(15)	449,878
Former President and	2015	422,692	127,500		183,938	(7)	—	13,459	(16)	747,589
Chief Scientific Officer	2014	350,000	294,000		—		3,507,672	13,258		4,164,930
Jeffrey E. Young(17)	2016	299,616	—		—		—	378,063	(18)	677,679
Former Chief Financial Officer	2015	308,500	114,000		367,875	(7)	—	7,973	(19)	798,348
Paul Chapman(20)	2016	351,442	75,000	(21)	—		1,712,981	320,949	(22)	2,460,372
Former Chief Operating Officer

(1): These amounts reflect the grant date fair value of stock options computed in accordance with the provisions of ASC 718. The assumptions that we used to calculate these amounts are discussed in Notes 2 and 8 to our financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016.
(2): This amount includes Dr. Dipp's 2016 annual bonus of $183,000 awarded under our 2016 annual bonus program and $150,000 retention bonus paid in accordance with Dr. Dipp's employment agreement.
(3): This amount reflects the value of life insurance, accidental death and dismemberment, short term disability and long term disability premiums and safe harbor matches under our 401(k) plan, equal to $10,600.
(4): Dr. Dipp earned certain portions of performance-based stock units granted in 2014 during 2015. The assumptions used to determine the compensation expense recorded related to the performance-based stock units and other awards are discussed in Notes 2 and 8 to our financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015.
(5): Includes an additional bonus of $99,988 for performance in the fiscal year ended December 31, 2014 that was paid in the fiscal year ended December 31, 2015. This bonus was paid in 2,375 fully vested shares of common stock based on the closing price of our common stock on March 3, 2015, the date of board approval of the bonus amount. After appropriate tax withholdings, Dr. Dipp received 1,477 shares of common stock.
(6): This amount reflects the grant date fair value, $335,806, of performance-based restricted stock units that vested on December 31, 2015 computed in accordance with the provisions of ASC 718, excluding the impact of estimated forfeitures. The assumptions that we used to calculate this amount is discussed in Note 8 to our financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015. The grant date fair value of the performance-based restricted stock units granted to Dr. Dipp in 2015, assuming the maximum potential value is achieved, is $503,709.
(7): This amount reflects the grant date fair value of time-based restricted stock units granted to Dr. Dipp in 2014 computed in accordance with the provisions of ASC 718, as well as performance-based restricted stock units that vested on December 31, 2014 computed in accordance with the provisions of ASC 718, excluding the impact of estimated forfeitures. The assumptions that we used to calculate this amount is discussed in Note 8 to our financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015.
(8): This amount includes Mr. Couturier's 2016 annual bonus of $134,200 awarded under our 2016 annual bonus program and a $5,000 discretionary bonus provided to Mr. Couturier for his efforts in connection with the 2016 restructuring initiative.

Table of Contents

(9): This amount reflects the grant date fair value of time-based restricted stock units computed in accordance with the provisions of ASC 718. The assumptions that we used to calculate this amount is discussed in Note 8 to our financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016.
(10): This amount reflects the value of life insurance, accidental death and dismemberment, short term disability and long term disability premiums and safe harbor matches under our 401(k) plan, equal to $4,554.
(11): Dr. Stock resigned from the company effective December 21, 2016.
(12): Amount represents a one-time sign-on bonus paid to Dr. Stock paid upon commencing employment with the company.
(13): This amount includes severance of $758,333 to be paid out over 14 months in accordance with Dr. Stock's separation agreement, payments of $60,100 for accrued vacation upon Dr. Stock's separation from the company, housing allowance of $119,351 and safe harbor matches under our 401(k) plan equal to $10,600, the value of life insurance, accidental death and dismemberment, and short term disability and long term disability premium.
(14): Dr. Tzianabos resigned from the company effective March 31, 2016.
(15): This amount includes severance payments of $212,500, payments of $9,808 for accrued vacation upon Dr. Tzianabos separation from the company, consulting fees of $95,188, safe harbor matches under our 401(k) plan equal to $9,459, the value of life insurance, accidental death and dismemberment, and short term disability and long term disability premium.
(16): This amount reflects safe harbor matches under our 401(k) plan equal to $10,600, the value of life insurance, accidental death and dismemberment, and short term disability and long term disability premiums.
(17): Mr. Young resigned from the company effective September 6, 2016.
(18): This amount includes severance payments of $190,000, bonus payment of $150,000 upon separation with the Company in accordance with Mr. Young's separation agreement, payments of $21,923 for accrued vacation upon Mr. Young's separation from the company and safe harbor matches under our 401(k) plan equal to $10,600, the value of life insurance, accidental death and dismemberment, and short term disability and long term disability premium.
(19): This amount reflects the value of life insurance, accidental death and dismemberment, short term disability and long term disability premiums and safe harbor matches under our 401(k) plan, equal to $5,116.
(20): Mr. Chapman resigned from the company effective December 21, 2016.
(21): Mr. Chapman's employment agreement provided for a $25,000 cash bonus for each quarter as long as Mr. Chapman remained employed with the company as of the respective quarter. The amount represents the bonus payment for the first three quarters of 2016.
(22): This amount includes severance payments of $283,333, payments of $20,514 for accrued vacation upon Mr. Chapman's separation from the company and safe harbor matches under our 401(k) plan equal to $10,600, the value of life insurance, accidental death and dismemberment, and short term disability and long term disability premium.

2016 Fiscal Year Grants Of Plan-Based Awards

The following table shows information regarding grants of non-equity incentive plan awards and grants of equity awards that we made during the fiscal year ended December 31, 2016 to each of our executive officers named in the Summary Compensation Table.

			Estimated Future Payouts Under Equity Incentive Plan Awards

															Grant Date Fair Value of Stock and Option Awards ($)
													Exercise or Base Price of Option Awards ($)
Name	Grant Date		Threshold (#)		Target (#)		Maximum (#)						Exercise or Base Price of Option Awards ($)
Michelle Dipp, M.D., Ph.D.		—		—		—		—	—							—
Christophe Couturier		9/8/2016		—		—		—	50,000	(1)	200,000	(2)		7.15		1,392,552
Harald Stock, Ph.D.		—		—		—		—	250,000	(1)	250,000	(2)		9.42		3,966,388
Jeffrey E. Young		—		—		—		—	—							—
Arthur Tzianabos, Ph.D.		—		—		—		—	—							—
Paul Chapman		3/3/2016		—		—		—	—		350,000	(2)		6.96		1,712,981

(1): Represents a time-based restricted stock unit award granted to the executive.
(2): Represents a stock option award granted to the executive at the time of commencing employment with the company.

Table of Contents

Outstanding Equity Awards at Fiscal Year End

The following table sets forth information regarding outstanding equity awards held by our Named Executive Officers as of December 31, 2016.

	Option Awards									Stock Awards

	Number of Securities Underlying Unexercised Options (#)		Number of Securities Underlying Unexercised Options (#)
										Number of Shares or Units of Stock That Have Not Vested (#)			Market Value of Shares or Units of Stock That Have Not Vested ($)(1)
					Option Exercise Price ($/Sh)
								Option Expiration Date
Name	Exercisable		Unexercisable					Option Expiration Date
Michelle Dipp, M.D., Ph.D.		339,313		—		7.80	(2)		12/4/2022		—			—
		312,500		187,500		8.43	(3)		6/12/2024		—			—
		100,000		100,000		32.36	(4)		12/8/2024		—			—
Christophe Couturier		—		200,000		7.15	(5)		9/7/2026		50,000	(6)		76,500
Harald Stock, Ph.D.		8,650		—		8.50	(7)		2/7/2023
		4,448		—		14.00	(8)		6/7/2023
		6,500		—		8.43	(9)		6/12/2024
		12,000		—		36.19	(10)		6/4/2025
Arthur Tzianabos, Ph.D.		253,500		—		14.27	(11)		9/9/2023		—			—
		123,750		—		8.58	(12)		12/4/2023		—			—
		135,000		—		32.36	(4)		12/8/2024		—			—
Jeffrey E. Young		—		—		—			—		—			—
Paul Chapman		—		—		—			—		—			—

(1): The market value of the stock awards is based on the fair value price of our common stock of $1.53 per share at December 31, 2016.
(2): This option award started vesting on March 31, 2013 and was fully vested as December 31, 2016.
(3): This option award started vesting on September 13, 2014 and vests in approximately equal quarterly installments through June 2018.
(4): This option award vests with respect to 25% of the shares on the first anniversary of the date of grant, which was December 9, 2014, and with respect to the remaining shares in approximately equal quarterly installments through the fourth anniversary of the date of grant.
(5): This option award vests with respect to 25% of the shares on the first anniversary of the date of grant, which was September 6, 2016, and with respect to the remaining shares in approximately equal quarterly installments through the fourth anniversary of the date of grant.
(6): This restricted stock unit award vests with respect to 25% of the shares on the first anniversary of the date of grant, which was September 6, 2016, and with respect to the remaining shares in approximately equal quarterly installments through the fourth anniversary of the date of grant.
(7): This option award vested ratably over twelve months following the date of grant, which was February 8, 2013 and were fully vested as of February 8, 2014. Pursuant to the Separation Agreement that we entered into with Dr. Stock on December 21, 2016, Dr. Stock is entitled to exercise the options until March 21, 2017.
(8): This option award vested ratably over twelve months following the date of grant, which was June 7, 2013 and were fully vested as of June 7, 2014. Pursuant to the Separation Agreement that we

Table of Contents

entered into with Dr. Stock on December 21, 2016, Dr. Stock is entitled to exercise the options until March 21, 2017.

(9): This option award vested ratably over twelve months following the date of grant, which was June 14, 2014 and were fully vested as of June 13, 2015. Pursuant to the Separation Agreement that we entered into with Dr. Stock on December 21, 2016, Dr. Stock is entitled to exercise the options until March 21, 2017.
(10): This option award vested ratably over twelve months following the date of grant, which was June 4, 2015 and were fully vested as of June 4, 2016. Pursuant to the Separation Agreement that we entered into with Dr. Stock on December 21, 2016, Dr. Stock is entitled to exercise the options until March 21, 2017.
(11): This option award vests with respect to 25% of the shares on the first anniversary of the date of hire, which was September 3, 2013, and with respect to the remaining shares in approximately equal quarterly installments through the fourth anniversary of the date of hire. This non-qualified stock option was issued as an inducement award outside of the 2012 Stock Incentive Plan.
(12): This option award vests with respect to 25% of the shares on the first anniversary of the date of grant, which was December 5, 2013, and with respect to the remaining shares in approximately equal quarterly installments through the fourth anniversary of the date of grant.

Option Exercises and Stock Vested in 2016

The following table shows information regarding exercises of options to purchase our common stock and vesting of stock awards held by each executive officer named in the Summary Compensation Table during the fiscal year ended December 31, 2016.

	Stock Awards

Name	Number of Shares Acquired on Vesting (#)			Value Realized on Vesting ($)
Arthur Tzianabos, Ph.D.		6,250	(1)		20,188

(1): 6,250 shares vested on December 3, 2016 as a result of vesting of time-based restricted stock units, and the value realized is calculated by multiplying the number of vested shares by the closing price of our common stock on the NASDAQ Global Market on the applicable vesting date.

Employment Agreements and Separation Agreements

Michelle Dipp, M.D., Ph.D.

In connection with Dr. Dipp's appointment to Executive Chair, on January 5, 2016, OvaScience entered into a five year employment agreement, or the EC Agreement, with Dr. Dipp. Pursuant to the EC Agreement, Dr. Dipp receives an annual base salary of $500,000 per year. In addition, Dr. Dipp may be awarded an annual target bonus of up to 60% of her then-current annual base salary, provided that the annual bonus may equal up to 90% of her then-current base salary if Dr. Dipp achieves over 100% of her performance objectives. The bonus award, if any, will be determined by the company's Board or a committee thereof and will be based upon the achievement of specific corporate goals, as determined by the Board or a committee thereof. The EC Agreement will expire on December 31, 2020, unless earlier terminated in accordance with its terms.

Pursuant to the EC Agreement, Dr. Dipp's options to purchase common stock outstanding in January 2016 will continue to vest pursuant to their current vesting schedule while Dr. Dipp serves as

Table of Contents

Executive Chair. The unvested portions of Dr. Dipp's time-based and performance-based restricted stock unit awards issued in December 2014 were terminated because these awards were in place in lieu of cash compensation for Dr. Dipp for fiscal years 2015 and 2016. Dr. Dipp did not receive any new equity grant in connection with entering the EC Agreement. Dr. Dipp's previous employment agreement, that was entered into in December 2014, provided that a tax gross-up would be paid on Dr. Dipp's behalf if any amounts payable by the company (or a successor) to her became subject to excise taxes under Sections 280G and 4999 of the Internal Revenue Code, the 280G tax gross-up provision. In connection with entering into the EC Agreement, Dr. Dipp agreed to eliminate this 280G tax gross-up provision. The EC Agreement also includes a retention agreement that provides that Dr. Dipp will be entitled to receive $37,500 on the last day of each quarter ending between March 31, 2016 and December 31, 2017 for so long as Dr. Dipp is employed by OvaScience at the end of the applicable quarter.

Christophe Couturier

Mr. Couturier joined the Company in August 2016, pursuant to the terms of an offer letter in which we agreed to employ Mr. Chapman on an at-will basis. Mr. Couturier's 2016 base salary was $400,000 pursuant to the terms of our employment agreement with him. Mr. Couturier is eligible to receive an annual bonus of up to 50% of his base salary, as determined by our Board in its sole discretion based on the achievement of performance goals determined by our Chief Executive Officer in consultation with the Board. Mr. Couturier is also bound by the terms of agreements covering non-solicitation, non-competition, confidential information and inventions assignment, which, among other things, prevents him from competing with us during the term of his agreement and for a specified time thereafter.

Harald Stock, Ph.D.

Dr. Stock resigned from the Company in December 2016. In January 2016, we entered into a five year employment agreement, or the Stock Agreement, with Dr. Stock. Pursuant to the Stock Agreement, Dr. Stock received an annual base salary of $650,000 in 2016. In addition, the Stock Agreement provided that Dr. Stock was eligible to receive an annual target bonus of up to 60% of his annual base salary to be determined by the Board or a committee thereof, provided that the annual bonus award may equal 90% of his then-current base salary if Dr. Stock's performance objective achievement was 120% or higher. Dr. Stock also received a sign-on bonus of $200,000. The Company also agreed to pay for or reimburse him for reasonable costs and expenses related to his relocation from Germany and provide him with a net housing allowance of $6,000 per month.

In connection with Dr. Stock's resignation, we entered into a separation agreement with Dr. Stock in December 2016. Pursuant to the terms and conditions of the separation agreement, Dr. Stock was entitled to receive fourteen months of his gross bi-weekly salary, to be paid pursuant to our normal payroll practices until February 28, 2018, and continuation of health benefits until February 28, 2018.

Arthur Tzianabos, Ph.D.

On March 31, 2016, Dr. Tzianabos resigned from the role of President and Chief Scientific Officer to assume the role of Chief Executive Officer at an early stage biotechnology company. We and Dr. Tzianabos entered into a Consulting Agreement which provided for Dr. Tzianabos to act as an advisor to us through December 31, 2016 to facilitate an orderly transition of his employment duties and responsibilities, meet with and educate third parties about us and our science, and perform special projects as identified by us.

We and Dr. Tzianabos also entered into a Separation Agreement in March 2016 pursuant to which he received (i) six months of his current annual base salary, paid out pursuant to our normal payroll

Table of Contents

practices over the next six months; (ii) continued vesting of his unvested stock option and unvested restricted stock unit awards during the time that he is advising with us; and (iii) extension of the exercise period of all his stock option awards until the later of (a) March 31, 2017 or (b) three months after the termination of the Consulting Agreement. Pursuant to the Consulting Agreement, Dr. Tzianabos received a flat fee of $8,333 per month while he advised us.

Jeffrey E. Young

Mr. Young resigned from the Company in September 2016. In July 2014, we entered into an employment agreement with Mr. Young pursuant to which we agreed to employ Mr. Young on an at-will basis. Effective December 1, 2015, Mr. Young's base salary was $380,000. Mr. Young's employment agreement provided that he was eligible to receive an annual bonus of up to 50% of his base salary, as determined by our Board in its sole discretion on the achievement of performance goals determined by our Chief Executive Officer in consultation with the Board. Mr. Young is also bound by the terms of agreements covering non-solicitation, non-competition, confidential information and inventions assignment, which, among other things, prevents him from competing with us during the term of his agreement and for a specified time thereafter.

Paul Chapman

Mr. Chapman resigned from the Company in December 2016. Mr. Chapman joined the Company in February 2016, pursuant to the terms of an offer letter in which we agreed to employ Mr. Chapman on an at-will basis. Mr. Chapman's 2016 base salary was $425,000 and he was eligible for an annual bonus of up to 50% of his base salary, as determined by our Board in its sole discretion on the achievement of performance goals determined by our Chief Executive Officer in consultation with the Board. We will also agreed to pay Mr. Chapman a retention bonus of up to $100,000, payable in equal quarterly installments at the end of each quarter of fiscal year 2016, provided that Mr. Chapman was employed by the company on each payment date. As an inducement to accepting the appointment as our new Chief Operating Officer, Mr. Chapman received a grant of an option to purchase 350,000 shares of common stock of the company, at an exercise price of $6.96, the closing price of the company's common stock on the NASDAQ Global Market on the date of grant of the stock option. The stock option had a ten-year term, vesting over four years, with 25% of the shares vesting on February 25, 2017 and 6.25% of the shares vesting each quarter thereafter. The stock option terminated when he left the Company. Mr. Chapman is also bound by the terms of agreements covering non-solicitation, non-competition, confidential information and inventions assignment, which, among other things, prevents him from competing with us during the term of his agreement and for a specified time thereafter.

In connection with Mr. Chapman's resignation, we entered into a separation agreement with Mr. Chapman in December 2016. Pursuant to the terms and conditions of the separation agreement, Mr. Chapman was entitled to receive eight months of his gross bi-weekly salary, to be paid pursuant to our normal payroll practices until August 31, 2017, and continuation of health benefits until August 31, 2017.

2016 Bonus Payments

In January 2017, after the Compensation Committee determined that the Company had achieved 61% of its corporate goals, and approved cash bonus payments to Dr. Dipp and Mr. Couturier in the

Table of Contents

amounts of $183,000 and $134,200, respectively. See "Compensation Discussion and Analysis—Elements of Executive Compensation—Annual Bonuses".

Potential Payments upon Termination or Change in Control

We have entered into agreements and maintain certain plans that may require us to make certain payments and/or provide certain benefits to the executive officers named in the Summary Compensation Table that were employed as executives on December 31, 2016 in the event of a termination of employment or a change of control.

Severance and Change of Control Arrangement with Dr. Dipp

Pursuant to Dr. Dipp's EC Agreement, Dr. Dipp will be entitled to severance benefits if we terminate her employment "without cause" or if Dr. Dipp terminates employment with us for "good reason" (each as defined below). If Dr. Dipp's employment terminates under these circumstances, we will be obligated to (1) provide that all outstanding and unvested stock options and restricted stock unit awards subject to time-based vesting will vest, on the date of such termination, as to the amount that would have vested over the six-month period following such termination; (2) pay Dr. Dipp her base salary for a period of six months and (3) pay the monthly premiums for COBRA coverage equal to the amount paid for similarly situated employees for a period of six months.

Upon a "change of control" (as defined below), all of Dr. Dipp's outstanding and unvested stock options will immediately vest on the date of such change of control.

Severance and Change of Control Arrangement with Mr. Couturier

Pursuant to Mr. Couturier's offer letter, Mr. Couturier will be entitled to severance benefits if we terminate his employment "without cause" or if Mr. Couturier terminates employment with us for "good reason" (each as defined below). If Mr. Couturier's employment terminates under these circumstances, we will be obligated to pay (1) Mr. Couturier his base salary for a period of six months and (2) the monthly premiums for COBRA coverage equal to the amount paid for similarly situated employees for a period of six months.

If Mr. Couturier's employment terminates under these circumstances within 12 months following a "change in control" (as defined below), in addition to the severance described above, we will be obligated to accelerate in full the vesting of the initial equity award granted to such officer when he was initially hired.

Defined Terms in Severance and Change of Control Agreements

As defined in Dr. Dipp's employment agreement:

" Cause " constitutes the following: (i) willful failure to perform, or gross negligence in the performance of, material duties and responsibilities to the Company and its Affiliates, which failure or negligence is not remedied within thirty (30) days of written notice thereof; (ii) material breach of any material provision of the EC Agreement or any other agreement with the Company or any of its Affiliates, which breach is not remedied within thirty (30) days of written notice thereof; (iii) fraud, embezzlement or other dishonesty with respect to the Company or any of its Affiliates, taken as a whole, which, in the case of such other dishonesty, causes or could reasonably be expected to cause material harm to the Company or any of its Affiliates, taken as a whole; or (iv) conviction of a felony.

Table of Contents

" Good Reason " means, without the executive's consent, the occurrence of any one or more of the following events, provided (x) the executive has furnished written notice to the Company of the condition giving rise to the claimed Good Reason no later than thirty (30) days following the occurrence of such condition, (y) the Company has failed to remedy the condition within thirty (30) days thereafter and (z) the executive's employment with the Company terminates within six months following the delivery of such notice:

(i): a material diminution in the nature or scope of the executive's responsibilities, duties or authority, provided that in the absence of a Change of Control any diminution in the nature or scope of the executive's responsibilities, duties or authority that is reasonably related to a diminution of the business of the Company or any of its Affiliates shall not constitute "Good Reason";
(ii): a failure of the Company to provide the executive with equity awards in accordance with the executive's employment agreement after thirty (30) days' notice during which the Company does not cure such failure;
(iii): relocation of the executive's office more than fifty (50) miles from the location of the Company's principal offices as of the date of the executive's employment agreement; or
(iv): the Company's failure to continue the executive's appointment or election as a director or officer of any of its Affiliates or the Company's or failure to continue the executive's appointment at his or her current position as a director and/or officer or the failure of the executive to be elected as a member of the Board, if the director serves as a member of the Board as of the date of his or her employment agreement.

" Change of Control " means (i) the acquisition of beneficial ownership (as defined in Rule 13-3 under the Exchange Act) directly or indirectly by any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act), of securities of the Company representing a majority or more of the combined voting power of the Company's then outstanding securities, other than in an acquisition of securities for investment purposes pursuant to a bona fide financing of the Company; (ii) a merger or consolidation of the Company with any other corporation in which the holders of the voting securities of the Company prior to the merger or consolidation do not own more than 50% of the total voting securities of the surviving corporation; or (iii) the sale or disposition by the Company of all or substantially all of the Company's assets other than a sale or disposition of assets to an Affiliate of the Company or a holder of securities of the Company; notwithstanding the foregoing, no transaction or series of transactions shall constitute a Change of Control unless such transaction or series of transactions constitutes a "change in control event" within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(i).

" Affiliates " means all persons and entities directly or indirectly controlling, controlled by or under common control with the Company, where control may be by management authority, equity interest or otherwise.

As defined in Mr. Couturier's employment agreement:

" Cause " for termination shall be deemed to exist upon:

(A): a good faith finding by the Company (i) of repeated or willful failure of the employee, after written notice, to perform his or her reasonably assigned duties for the Company, or (ii) that the employee has engaged in dishonesty, gross negligence or misconduct, which dishonesty, gross negligence or misconduct has had a material adverse effect on the business or affairs of the Company;
(B): the conviction of the employee of, or the entry of a pleading of guilty or nolo contendere by the employee to, any crime involving moral turpitude or any felony; or

Table of Contents

(C): a breach by the employee of any material provision of any invention and non-disclosure agreement or non-competition and non-solicitation agreement with the Company, which breach is not cured within a 10-day written notice thereof.

A " Change in Control Event " shall be deemed to exist upon the sale of all or substantially all of the outstanding shares of capital stock, assets or business of the Company, by merger, consolidation, sale of assets or otherwise (other than a transaction in which all or substantially all of the individuals and entities who were beneficial owners of the capital stock of the Company immediately prior to such transaction beneficially own, directly or indirectly, more than 50% of the outstanding securities (on an as-converted to Common Stock basis) entitled to vote generally in the election of directors of the (i) resulting, surviving or acquiring corporation in such transaction in the case of a merger, consolidation or sale of outstanding shares, or (ii) acquiring corporation in the case of a sale of assets).

" Good Reason " shall be deemed to exist upon:

(A): the relocation of the Company's offices such that the employee's daily commute is increased by at least 30 miles each way without the written consent of the employee;
(B): material reduction of the employee's annual base salary without the prior consent of the employee (other than in connection with, and substantially proportionate to, reductions by the Company of the annual base salary of more than 50% of its employees); or
(C): material diminution in employee's duties, authority or responsibilities without the prior consent of the employee, other than changes in duties, authority or responsibilities resulting from the employee's misconduct;

provided, however, that (i) no such event or condition shall constitute Good Reason unless (x) the employee gives the Company a written notice of termination for Good Reason not more than 90 days after the initial existence of the condition, (y) the grounds for termination if susceptible to correction are not corrected by the Company within 30 days of its receipt of such notice and (z) the employee's termination of employment occurs within six months following the Company's receipt of such notice; and (ii) at all times "Good Reason" will be interpreted in a manner consistent with the definition of "good reason" within the meaning of Section 409A.

Potential Payments Upon Termination (as of December 31, 2016)

The following table summarizes the potential payments to our Named Executive Officers under the severance and change of control agreements assuming that a termination occurred under the circumstances set forth in the column headings. The information presented assumes that the termination occurred on December 31, 2016, the last business day of our most recently completed fiscal

Table of Contents

year. The closing price of our common stock as listed on The NASDAQ Global Market on December 30, 2016, the last trading day of our fiscal year, was $1.53 per share.

Name	Executive Payments and Benefits upon Termination	Termination without Cause or Resignation for Good Reason		Termination without Cause or Resignation for Good Reason within One Year Following a Change of Control

Michelle Dipp, M.D., Ph.D. Executive Chair	Base salary	$	250,000	$	250,000
	Acceleration of Vesting of Equity		6 months		—		100	%
	Number of Vesting In-The-Money Stock Options and Value upon Termination		—		—		—
	Cobra Benefits		—		—

	Total	$	250,000	$	250,000		—
Christophe Couturier Chief Financial Officer	Base Salary	$	200,000	$	200,000		—
	Acceleration of Vesting of Certain Equity		N/A		100	%
	Number of Vesting In-The-Money stock		—		0		—
	Options and Value upon Termination				0		—
	Cobra Benefits	$	8,954	$	8,954

	Total	$	208,954	$	208,954

For a description of the actual amounts received by Dr. Stock following his resignation, see "Employment Agreements and Separation Agreements—Harald Stock, Ph.D." above.

For a description of the actual amounts received by Dr. Tzianabos following his resignation, see "Employment Agreements and Separation Agreements—Arthur Tzianabos, Ph.D." above.

For a description of the actual amounts received by Mr. Young following his resignation, see "Employment Agreements and Separation Agreements—Jeffrey Young" above.

For a description of the actual amounts received by Mr. Chapman following his resignation, see "Employment Agreements and Separation Agreements—Paul Chapman" above.

401(k) Retirement Plan

We maintain a defined contribution employee retirement plan for our employees. Our 401(k) plan is intended to qualify as a tax-qualified plan under Section 401 of the Code, so that contributions to our 401(k) plan, and income earned on such contributions, are not taxable to participants until withdrawn or distributed from the 401(k) plan. Our 401(k) plan provides that each participant may contribute up to 100% of his or her pre-tax compensation, up to a statutory limit, which is $18,000 for

Table of Contents

2016. Participants who are at least 50 years old can also make "catch-up" contributions, which in 2016 may be up to an additional $6,000 above the statutory limit. Under our 401(k) plan, each employee is fully vested in his or her deferred salary contributions. Employee contributions are held and invested by the plan's trustee. Our 401(k) plan also permits us to make discretionary contributions and matching contributions, subject to established limits and a vesting schedule. Beginning in January 2012, we made an employer matching contribution equal to (1) 100% of employee deferral contributions up to a deferral rate of 3% of compensation plus (2) 50% of employee deferral contributions up to a deferral rate of an additional 2% of compensation.

Securities Authorized for Issuance Under Our Equity Compensation Plans

The following table sets forth information regarding our equity compensation plans as of December 31, 2016.

Plan Category

Equity compensation plans approved by security holders(1)	2,960,942	18.32	1,467,522
Equity compensation plans not approved by security holders(2)	512,000	11.49	—

Total	3,472,942		1,467,522

(1): This plan category consists of our 2012 and 2011 Stock Incentive Plans.
(2): This plan category consists of inducement grants provided to Mr. Couturier, our Chief Financial Officer and Dr. Arthur Tzianabos, our former President and Chief Scientific Officer pursuant to the terms of our stock option agreements with them (as discussed below).

Stock Option Agreement with Mr. Couturier

Pursuant to a Stock Option Agreement with Mr Couturier, dated September 6, 2016, Mr. Couturier was granted an option to purchase 200,000 shares of Common Stock at a price per share of $7.15, as an inducement material to his entering into employment with us. The grant has a term of ten years and is subject to a vesting schedule of four years, with 25% of the shares vesting on September 6, 2017 and 6.25% of the shares vesting each quarter thereafter, subject to his continued employment with the Company.

Stock Option Agreement with Dr. Tzianabos

Pursuant to a Stock Option Agreement with Dr. Tzianabos, dated September 10, 2013, Dr. Tzianabos was granted an option to purchase 312,000 shares of Common Stock at a price per share of $14.27, as an inducement material to his entering into employment with us. The grant has a term of ten years and is subject to a vesting schedule of four years, with 25% of the shares vesting on September 3, 2014 and 6.25% of the shares vesting each quarter thereafter, subject to his continued employment with the Company. This stock option terminated in December 2016 and the option was not exercised with respect to any vested shares.

Table of Contents

DIRECTOR COMPENSATION

Our director compensation program is administered by our Board with the assistance of the Compensation Committee. The Compensation Committee conducts an annual review of director compensation and makes recommendations to the Board with respect thereto.

Based on the recommendation of our Compensation Committee, our Board adopted an amended and restated non-employee director compensation policy (the "2015 policy"). Under the 2015 policy, our non-employee directors were compensated for service on our Board as follows in 2016:

•: an annual retainer for our non-employee directors for service on our Board of $35,000;
•: for members of the Audit Committee, an annual fee of $8,000 ($15,000 for the chair);
•: for members of the Nominating and Corporate Governance Committee, an annual fee of $3,750 ($7,500 for the chair);
•: for members of the Compensation Committee, an annual fee of $5,000 ($10,000 for the chair);
•: to each newly elected director, an initial grant of a stock option to purchase 8,650 shares of our common stock, at an exercise price equal to the fair market value of our common stock on the date of grant, which option shall vest monthly over one year; and
•: for continuing service on our Board, an annual grant of a stock option to purchase 12,000 shares of our common stock, at an exercise price equal to the fair market value of our common stock on the date of grant, which option shall vest monthly over one year.

Subject to the director's continued service as a director, the initial and annual stock option grants vest in approximately equal monthly installments through the first anniversary of the grant date. The initial stock option grants were made on the date of each director's initial appointment or election to the Board.

Under the 2015 policy, we reimbursed our non-employee directors for their reasonable expenses incurred in connection with attending our Board and Committee meetings upon presentation of documentation of such expenses reasonably satisfactory to us.

Under the 2015 policy, our non-employee directors may elect to receive their annual fees for board and committee service from January 1 to December 31 of a given year in either cash or fully vested shares of our common stock. This election occurs on an annual basis.

The following table sets forth information regarding the total compensation awarded to, earned by or paid to each of our non-employee directors during the year ended December 31, 2016 for their service on our Board. Dr. Dipp, our Executive Chair, did not receive any additional compensation for

Table of Contents

her service as a director during 2016. The compensation that we pay to Dr. Dipp is discussed under "Executive Compensation" above.

Name

Richard Aldrich	—		42,500	62,363	104,863
Jeffrey D. Capello	50,000		—	62,363	112,363
Mary Fisher	20,000		20,000	62,363	102,363
Marc Kozin	30,000	(4)	38,750	62,363	131,113
Thomas Malley	—		53,000	62,363	115,363
John Sexton, Ph.D.	155,000	(5)	—	62,363	217,363
John Howe, III, M.D.	168,000	(5)	—	62,363	230,363

(1): Reflects payment of annual fees for board and committee service from January 1 to December 31 of a given year in fully vested shares of our common stock. Each payment is made at the end of each quarter based on the closing price of the Company's common stock on the last day of the quarter. As of December 31, 2016, our non-employee directors did not hold any shares under outstanding stock awards.
(2): The amounts in the "Option Awards" column reflect the aggregate grant date fair value of stock options granted during the year computed in accordance with the provisions of ASC 718. The assumptions that we used to calculate these amounts are discussed in Notes 2 and 8 to our financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016.
(3): As of December 31, 2016, our non-employee directors held the following aggregate number of shares under outstanding option awards (representing both exercisable and unexercisable option awards, none of which have been exercised):

Name		Number of Shares Underlying Outstanding Stock Options

Richard Aldrich			34,948
Jeffrey D. Capello			48,046
Mary Fisher			43,598
Marc Kozin			42,400
Thomas Malley			48,046
John Sexton, Ph.D.			32,650
John Howe, III, M.D.			32,650

(4): Represents fees for additional board services, as approved by the Board, in guiding the company in its long-term strategy, which services he continues to provide on the Global Strategy Committee.
(6): Represents (i) annual fees earned for service on the Board of Directors of $35,000 and $48,000 for Drs. Sexton and Howe, respectively and (ii) $120,000 for additional board services, as approved by the Board, in providing long-term strategic global regulatory guidance, which services Drs. Sexton and Howe continue to provide on the Global Strategy Committee.

Mr. Kozin and Drs. Sexton and Howe will receive compensation as members of the Global Strategy Committee. The Global Strategy Committee will support the Board in providing board level

Table of Contents

global strategic guidance to the Executive Chair, Chief Executive Officer and executive management team. The Global Strategy Committee's responsibilities include:

•: advising the Executive Chair, Chief Executive Officer and executive management team generally on global strategy, as well as on the development and implementation of the Company's strategic plan; and
•: advising the Executive Chair, Chief Executive Officer and executive management team on strategies for approaching international markets, including guidance on cultural, regulatory and government affairs matters.

For their service on the Global Strategy Committee, Mr. Kozin will receive monthly retainer payments of $2,500 and Drs. Sexton and Howe will receive monthly retainer payments of $10,000.

AUDIT RELATED MATTERS

Audit Committee Report

The Audit Committee of the Board of OvaScience, Inc., which consists entirely of directors who meet the independence and experience requirements of The Nasdaq Stock Market, has reviewed OvaScience's audited financial statements for the fiscal year ended December 31, 2016 and discussed them with management and the Company's independent auditors, Ernst & Young LLP, an independent registered public accounting firm.

The Audit Committee has received from, and discussed with, Ernst & Young LLP various communications that Ernst & Young LLP is required to provide to the Audit Committee, including the matters required to be discussed by Auditing Standard No. 16— Communications with Audit Committees .

The Audit Committee has received the written disclosures and the letter from Ernst & Young LLP required by applicable requirements of the Public Company Accounting Oversight Board regarding the independent registered public accounting firm's communications with the Audit Committee concerning independence, and has discussed with the Company's independent registered public accounting firm its independence.

Based on the review and discussions referred to above, the Audit Committee recommended to the OvaScience Board that the audited financial statements referred to above be included in OvaScience's Annual Report on Form 10-K for the fiscal year ended December 31, 2016.

By the Audit Committee of the Board of OvaScience, Inc.


		Jeffrey D. Capello (Chair) Thomas Malley John Howe, III, M.D.

Audit Fees and Services

The following table summarizes the fees of Ernst & Young LLP, our independent registered public accounting firm, billed to us for each of the last two fiscal years.

Fee Category	2016		2015

Audit Fees	$	766,846	$	666,137
Audit-Related Fees		—		10,000
Tax Fees		446,506		355,741
All Other Fees		1,800		2,265

Total Fees	$	1,215,152	$	1,034,143

Table of Contents

Audit Fees

Audit fees are fees related to professional services rendered in connection with the audit of our annual financial statements, the reviews of the interim financial statements included in each of our quarterly reports on Form 10-Q, the reviews of financial statements included in any registration statements we file with the SEC and other professional services provided by our independent registered public accounting firm in connection with statutory or regulatory filings or engagements, and the audit of our internal control over financial reporting required by Section 404 of the Sarbanes-Oxley Act of 2002.

Audit-Related Fees

Audit-related fees are fees for assurance and related services that are reasonably related to performance of the audit and review of financial statements, and which are not reported under "Audit Fees."

Tax Fees

Tax fees are fees for professional services for tax compliance, tax advice and tax planning services.

All Other Fees

Other fees include licensing fees that we paid to PricewaterhouseCoopers and Ernst & Young LLP in 2016 and 2015, respectively for access to their proprietary accounting research database.

All of the foregoing accountant services and fees were pre-approved by our Audit Committee in accordance with the policies and procedures described under "—Policy for Approval of Services" below.

Policy for Approval of Services

The Audit Committee of our Board has adopted policies and procedures for the pre-approval of audit and non-audit services for the purpose of maintaining the independence of our independent auditor. We may not engage our independent auditor to render any audit or non-audit service unless the service is approved in advance by the Audit Committee. Notwithstanding the foregoing, pre-approval is not required with respect to the provision of services, other than audit, review or attest services, by the independent auditor if the aggregate amount of all such services is no more than 5% of the total amount paid by us to the independent auditor during the fiscal year in which the services are provided, such services were not recognized by us at the time of the engagement to be non-audit services, and such services are promptly brought to the attention of the Audit Committee and approved prior to completion of the audit by the Audit Committee.

Table of Contents

MATTERS TO BE VOTED ON

Proposal 1: Election of Class II Directors

At the Annual Meeting, stockholders will vote to elect three class II directors, each to serve a three-year term beginning at the Annual Meeting and ending at our 2020 Annual Meeting of stockholders. Our Board has nominated Mr. Aldrich, Ms. Fisher and Dr. Sexton for election as class II directors at the Annual Meeting.

Pursuant to our certificate of incorporation and by-laws, our Board is divided into three classes, with each class having as nearly as possible an equal number of directors. The term of service of each class of directors is staggered so that the term of one class expires at each Annual Meeting of the stockholders. Upon the expiration of the term of a class of directors, directors in that class are eligible to be elected for a new three-year term at the Annual Meeting of stockholders in the year in which their term expires. Our Board currently consists of seven members, divided into three classes as follows:

•: class I consists of Dr. Howe and Mr. Kozin, each with a term expiring at the 2019 annual meeting of stockholders;
•: class II consists of Mr. Aldrich, Ms. Fisher and Dr. Sexton, each with a term expiring at the 2017 annual meeting of stockholders; and
•: class III consists of Dr. Dipp and Messrs. Capello and Malley, each with a term expiring at the 2018 annual meeting of stockholders.

Mr. Aldrich, Ms. Fisher and Dr. Sexton are current directors whose terms expire at the Annual Meeting. Mr. Aldrich, Ms. Fisher and Dr. Sexton are each nominated for re-election as a class II director, with a term ending in 2020. A brief biography of each director nominee is set forth starting on page 7 of this proxy statement. You will find information about their stock holdings in OvaScience below under "Ownership of Our Common Stock—Security Ownership of Certain Beneficial Owners and Management."

Unless contrary instructions are provided, the persons named as proxies will, upon receipt of a properly executed proxy, vote for the election of Mr. Aldrich, Ms. Fisher and Dr. Sexton as class II directors for a term expiring at our 2020 Annual Meeting of stockholders. Proxies cannot be voted for a greater number of persons than the number of nominees named. Each of the nominees is currently a member of our Board. Each of the nominees has indicated his or her willingness to serve on our Board, if elected. If any nominee should be unable to serve, proxies may be voted for a substitute nominee designated by our Board. We do not contemplate that any of the nominees will be unable to serve if elected.

A plurality of the shares voted is required to elect each nominee as a director.

Board Recommendation

Our Board recommends that you vote FOR the election of each of the nominees as a class II director.

Table of Contents

Proposal 2: Ratification of Appointment of Independent Auditors

The Audit Committee of our board has appointed the firm of Ernst & Young LLP, an independent registered public accounting firm, as our independent auditors for the current fiscal year. Ernst & Young LLP has served as our independent auditors since January 2012. Although stockholder approval of the appointment of Ernst & Young LLP is not required by law, our Audit Committee believes it is advisable and has decided to give our stockholders the opportunity to ratify this appointment. If this proposal is not approved at the Annual Meeting, our Audit Committee may reconsider this appointment.

The affirmative vote of a majority of votes cast affirmatively or negatively on the matter is required to approve this proposal.

Representatives of Ernst & Young LLP are expected to be present at the Annual Meeting and will have the opportunity to make a statement if they desire to do so. It is also expected that they will be available to respond to appropriate questions from stockholders.

Board Recommendation

Our Board recommends that you vote FOR the ratification of Ernst & Young LLP as our independent auditors for the fiscal year ending December 31, 2017.

Table of Contents

Proposal 3: Approval of Advisory Vote on the Compensation of Named Executive Officers

We are seeking your advisory vote as required by Section 14A of the Securities Exchange Act of 1934, as amended, on the approval of the compensation of our Named Executive Officers as described in the Compensation Discussion and Analysis, the compensation tables and related material contained in this proxy statement. Because your vote is advisory, it will not be binding on our Compensation Committee or our Board. However, the Compensation Committee and the Board will review the voting results and take them into consideration when making future decisions regarding executive compensation. The next advisory vote to approve the compensation of Named Executive Officers will occur at the 2018 annual meeting of stockholders.

We have a pay-for-performance philosophy whereby actual compensation levels are correlated to the achievement of corporate and individual goals. We believe that our executive compensation programs are strongly aligned with our performance on both a short-term and long-term basis, linked to results intended to create value for stockholders, and that such compensation assists us in attracting and retaining key executives critical to our long-term success. Consistent with this philosophy, a significant portion of the total compensation opportunity for each of our executives is directly related to performance factors that measure our progress against the goals of our strategic and operating plans.

During 2016, we made progress on our business goals, including:

•: We received IRB approval to begin an OvaPrime clinical trial in Canada, and have since begun enrolling and treating patients in our OvaPrime clinical trial, titled "A Single Center, Prospective, Controlled Pilot Study of OvaPrime Procedure," which is being performed to evaluate the safety of the OvaPrime procedure in subjects with poor ovarian response or diminished ovarian response.
•: We made the decision to move the OvaTure program forward. In December 2013, we entered into a collaboration with Intrexon, a leader in synthetic biology, to accelerate development of OvaTure, which we refer to as the OvaTure Collaboration. The companies also formed OvaXon LLC, a joint venture designed to develop applications to prevent inherited human diseases and improve animal health. In 2016, the OvaTure Collaboration and OvaXon generated data supporting the characterization and developmental competence of human and bovine EggPC cell derived-eggs, respectively.
•: We expanded the availability of the AUGMENT treatment in select international regions, and scheduled a meeting with the FDA in the first half of 2017 to explore potential entry into the U.S. market. We have since decided that while we would continue to make AUGMENT available to patients at partner clinics in Canada and Japan and maintain our current commercial footprint, we would slow our commercial expansion, reassess the ongoing and planned clinical studies of AUGMENT, and undertake a corporate restructuring.

Stockholders are urged to read the Compensation Discussion and Analysis section of this proxy statement, which discusses how our compensation policies and procedures implement our compensation philosophy. The Compensation Committee and the Board believe that these policies and procedures are effective in implementing our compensation philosophy and in achieving its goals.

In accordance with the rules of the SEC, the following resolution, commonly known as a "say-on-pay" vote, is being submitted for a stockholder vote at the Annual Meeting:

"RESOLVED, that the compensation paid to the Named Executive Officers of the Company, as disclosed pursuant to the compensation disclosure rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis, the compensation tables and the related material disclosed in this proxy statement, is hereby APPROVED."

Table of Contents

The affirmative vote of a majority of votes cast affirmatively or negatively on the matter is required to approve, on an advisory basis, this proposal.

Board Recommendation

Our Board recommends that you vote FOR the approval, on an advisory basis, of the compensation of our Named Executive Officers.

Table of Contents

OWNERSHIP OF OUR COMMON STOCK

Security Ownership of Certain Beneficial Owners and Management

The following table sets forth, as of April 10, 2017, certain information concerning the beneficial ownership of our capital stock by:

•: each director;
•: each Named Executive Officer;
•: all of our executive officers and directors as a group; and
•: each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of any class of our outstanding stock.

Beneficial ownership is determined in accordance with the rules and regulations of the SEC and includes voting or investment power with respect to our common stock. Shares of our common stock subject to options that are currently exercisable or exercisable within 60 days of April 10, 2017 and restricted stock units that will vest within 60 days of April 10, 2017 are considered outstanding and beneficially owned by the person holding the options or restricted stock units, as applicable, for the purpose of calculating the percentage ownership of that person but not for the purpose of calculating the percentage ownership of any other person. Except as otherwise noted, we believe the persons and entities in this table have sole voting and investing power with respect to all of the shares of our common stock beneficially owned by them, subject to community property laws, where applicable. The

Table of Contents

inclusion of any shares in this table does not constitute an admission of beneficial ownership by the person named below.

Name and Address of Beneficial Owner(1)

Directors and Executive Officers
Michelle Dipp, M.D., Ph.D.	1,779,983	(4)	4.88	%
Christophe Couturier	50,900		*
Harald Stock, Ph.D.	16,422	(5)	*
Arthur Tzianabos, Ph.D.	26,400		*
Jeffrey Young	53,750		*
Paul Chapman	3,100		*
Richard Aldrich	2,015,167	(6)	5.65	%
Jeffrey D. Capello	59,157	(7)	*
Mary Fisher	59,235	(8)	*
Marc Kozin	79,687	(9)	*
Thomas Malley	245,154	(10)	*
John Sexton, Ph.D.	32,650	(11)	*
John Howe, III, M.D.	32,650	(12)	*
All executive officers and directors as a group (13 persons)	3,492,199		9.50	%
5% Stockholders
Entities affiliated with FMR LLC	5,340,442	(13)	14.98	%
245 Summer Street
Boston, MA 02110
Entities affiliated with EcoR1 Capital, LLC	3,512,332	(14)	9.85	%
409 Illinois Street
San Francisco, CA 94158
Entities affiliated with Prudential Financial, Inc.	2,183,527	(15)	6.12	%
751 Broad Street
Newark, NJ 07102
BlackRock, Inc.	1,878,683	(16)	5.27	%
55 East 52 ^nd Street
New York, NY 10055

*: Less than 1%.
(1): Unless otherwise indicated, the address of such individual is c/o OvaScience, Inc., 9 Fourth Avenue, Waltham, Massachusetts 02451.
(2): Applicable number of shares of stock beneficially owned is calculated as of April 10, 2017.
(3): Applicable percentage ownership is based on 35,662,124 shares of our common stock outstanding as of April 10, 2017.
(4): Consists of (a) 971,921 shares of common stock held by Dr. Dipp, (b) 962,056 shares of common stock held by Longwood Fund III, LP and (c) options to purchase an aggregate of 808,062 shares of common stock held by Dr. Dipp that are exercisable within 60 days of April 10, 2017. Voting and investment power with respect to the shares held by Longwood Fund III GP, LLC are vested in Richard Aldrich, Michelle Dipp, M.D., Ph.D., and Christoph Westphal, M.D., Ph.D., the managers of Longwood Fund III GP LLC, the general partner of Longwood Fund III, LP.

Table of Contents

(5): Consists of (a) 1,228 shares of common stock held by Mr. Stock and (b) 15,194 shares of common stock held by SB Vermogensverwaltungs KG, a trust of which the Mr. Stock is a majority shareholder and managing partner.
(6): Consists of (a) 19,971 shares of common stock held directly by Mr. Aldrich, (b) 330,000 shares of common stock held by Little Eagles, LLC, whose owners are Richard H. Aldrich Irrevocable Trust of 2011 and trusts established for the benefit of the Mr. Aldrich's minor children, (c) 668,192 shares of common stock held by Richard H. Aldrich Irrevocable Trust of 2005, (d) options to purchase an aggregate of 34,948 shares of common stock held by Mr. Aldrich that are exercisable within 60 days of April 10, 2017 and (f) 971,921 shares of common stock held by Longwood Fund III, LP. The trustee of the Richard H. Aldrich Irrevocable Trust of 2011 is Mr. Aldrich and he exercises sole voting and investment power over the shares of record held by the trust. Voting and investment power with respect to the shares held by Longwood Fund III GP, LLC are vested in Richard Aldrich, Michelle Dipp, M.D., Ph.D., and Christoph Westphal, M.D., Ph.D., the managers of Longwood Fund III GP LLC, the general partner of Longwood Fund III, LP.
(7): Consists of (a) 11,111 shares of common stock held by Mr. Capello and (b) options to purchase an aggregate of 48,046 shares of common stock held by Mr. Capello that are exercisable within 60 days of April 10, 2017.
(8): Consists of 15,637 shares held by Ms. Fisher and 43,598 options to purchase shares of common stock held by Ms. Fisher that are exercisable within 60 days of April 10, 2017.
(9): Consists of (a) 37,287 shares of common stock held by Mr. Kozin and (b) options to purchase an aggregate of 42,400 shares of common stock held by Mr. Kozin that are exercisable within 60 days of April 10, 2017.
(10): Consists of (a) 197,108 shares of common stock held by Mr. Malley and (b) options to purchase an aggregate of 48,046 shares of common stock held by Mr. Malley that are exercisable within 60 days of April 10, 2017.
(11): Consists of options to purchase shares of common stock that are exercisable within 60 days of April 10, 2017.
(12): Consists of options to purchase shares of common stock that are exercisable within 60 days of April 10, 2017.
(13): This information is based solely on a Schedule 13G/A filed with the Securities and Exchange Commission on or about February 13, 2017. All 5,340,442 shares of common stock are beneficially owned by FMR LLC. Abigail P. Johnson is a Director, the Chairman, the Chief Executive Officer and the President of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR LLC nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies registered under the Investment Company Act ("Fidelity Funds") advised by Fidelity Management & Research Company ("FMR Co"), a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity Funds' Boards of Trustees. Fidelity Management & Research Company carries out the voting of the shares under written guidelines established by the Fidelity Funds' Boards of Trustees.

Table of Contents

(14): This information is based solely on a Schedule 13G/A filed with the Securities and Exchange Commission on or about March 31, 2017. Includes 3,512,332 shares of Common Stock beneficially owned by EcoR1 Capital, LLC. EcoR1 Capital Fund LLC is the general partner and investment adviser of investment funds, including EcoR1 Capital Fund Qualified, L.P. and Oleg Nodelman is the control person of EcoR1 Capital Fund LLC.
(15): This information is based solely on a Schedule 13G filed with the Securities and Exchange Commission on or about January 10, 2017.Consists of (a) 2,183,527 shares of common stock held by Jennison Associates LLC and (b) 2,960 shares of common stock held by Quantitative Management Associates LLC. Prudential Financial, Inc. is a parent holding company and indirect parent of Jennison Associates LLC and Quantitative Management Associates LLC.
(16): This information is based solely on a Schedule 13G filed with the Securities and Exchange Commission on or about January 30, 2017. BlackRock, Inc. reported sole voting power over 1,826,192 shares and sole dispositive power over 1,878,683 shares on behalf of the following subsidiaries: BlackRock Advisors, LLC, BlackRock Asset Management Canada Limited, BlackRock Asset Management Ireland Limited, BlackRock Asset Management Schweiz AG, BlackRock Fund Advisors, BlackRock Institutional Trust Company, N.A., and BlackRock Investment Management, LLC.

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Securities Exchange Act requires our directors and officers and holders of more than 10% of our common stock to file with the SEC initial reports of ownership of our common stock and other equity securities on a Form 3 and reports of changes in such ownership on a Form 4 or Form 5. Directors and officers and holders of 10% of our common stock are required by SEC regulations to furnish us with copies of all Section 16(a) forms they file. Our records reflect all reports which were required to be filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, as amended, were filed on a timely basis, except for a Form 4 of Christophe Couturier filed on March 13, 2017 reporting a purchase of common stock, which was inadvertently filed late.

Table of Contents

OTHER MATTERS

Our Board does not know of any other matters that may come before the Annual Meeting. However, if any other matters are properly presented to the Annual Meeting, it is the intention of the persons named in the accompanying proxy to vote, or otherwise act, in accordance with their judgment on such matters.

STOCKHOLDER PROPOSALS

Deadline for Submission of Stockholder Proposals for 2018 Annual Meeting

Proposals of stockholders intended to be presented at the 2018 Annual Meeting of the stockholders, pursuant to Rule 14a-8 promulgated under the Exchange Act, and stockholder-submitted nominees for directors, must be received by our Secretary in writing at our principal offices, OvaScience, Inc., 9 Fourth Avenue, Waltham, Massachusetts 02451, Attention: Investor Relations, no later than December 25, 2017, in order to be included in the proxy statement and proxy card relating to that meeting.

If a stockholder wishes to present a proposal at our 2018 Annual Meeting of stockholders, but does not wish to have the proposal considered for inclusion in our proxy statement and proxy card, such stockholder must give written notice to the Secretary of the Company at our principal executive offices at the address noted above. The Secretary must receive such notice no earlier than February 8, 2018 and no later than March 10, 2018, provided that if the date of the Annual Meeting is advanced by more than 20 days, or delayed by more than 60 days, from the first anniversary of the Annual Meeting, such notice must instead be received by the Secretary no earlier than the 120 ^th day prior to the Annual Meeting and not later than the later of (i) the 90 ^th day prior to the 2018 Annual Meeting and (ii) the tenth day following the day on which notice of the date of the 2018 Annual Meeting was mailed or public disclosure of the date of the 2018 Annual Meeting was made, whichever occurs first.

VOTE BY INTERNET - www.proxyvote.com Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 P.M. Eastern Time on June 7, 2017. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form. OVASCIENCE, INC. 9 4TH AVENUE WALTHAM, MA 02451 ATTN: CHRISTOPHE COUTURIER ELECTRONIC DELIVERY OF FUTURE PROXY MATERIALS If you would like to reduce the costs incurred by our company in mailing proxy materials, you can consent to receiving all future proxy statements, proxy cards and annual reports electronically via e-mail or the Internet. To sign up for electronic delivery, please follow the instructions above to vote using the Internet and, when prompted, indicate that you agree to receive or access proxy materials electronically in future years. VOTE BY PHONE - 1-800-690-6903 Use any touch-tone telephone to transmit your voting instructions up until 11:59 P.M. Eastern Time on June 7, 2017. Have your proxy card in hand when you call and then follow the instructions. VOTE BY MAIL Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: E26343-P92015 KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. OVASCIENCE, INC. The Board of Directors recommends you vote FOR each of the Class II Director nominees: For Withhold AllAll For All Except To withhold authority to vote for any individual nominee(s), mark “For All Except” and write the number(s) of the nominee(s) on the line below. ! ! ! 1. Election of Class II Directors Nominees: 01) Richard Aldrich 02) Mary Fisher 03) John Sexton, Ph.D. For Against Abstain The Board of Directors recommends you vote FOR proposal 2. ! ! ! 2. To ratify the appointment of Ernst & Young LLP, an independent registered public accounting firm, as the independent auditors of OvaScience for the fiscal year ending December 31, 2017. The Board of Directors recommends you vote FOR proposal 3. ! ! ! 3. Proposal to approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed pursuant to the compensation disclosure rules of the Securities and Exchange Commission. ! For address changes and/or comments, please check this box and write them on the back where indicated. Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized officer. Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date V.1.1

Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: The Notice, Proxy Statement and Annual Report are available at www.proxyvote.com. E26344-P92015 OVASCIENCE, INC. 2017 Annual Meeting of Stockholders To be held Thursday, June 8, 2017 at 11:00 a.m., Eastern Time This proxy is solicited by the Board of Directors The undersigned, having received notice of the Annual Meeting of Stockholders and the proxy statement therefor and revoking all prior proxies, hereby appoints each of Michelle Dipp, M.D., Ph.D. and Christophe Couturier (each with full power of substitution), as Proxies of the undersigned, to attend the Annual Meeting of Stockholders of OvaScience to be held at 11:00 a.m., Eastern Time, on Thursday, June 8, 2017, at 70 3rd Avenue, Waltham, Massachusetts 02451, and any adjourned or postponed session thereof, and there to vote and act as indicated upon the matters on the reverse side in respect to all shares of common stock which the undersigned would be entitled to vote or act upon, with all powers the undersigned would possess if personally present. You can revoke your proxy at any time before it is voted at the annual meeting (i) by submitting another properly completed proxy bearing a later date; (ii) by giving written notice of revocation to the Secretary of OvaScience; (iii) if you submitted a proxy through the Internet or telephone, by submitting a proxy again through the Internet or by telephone prior to the close of the Internet voting facility or the telephone voting facility; or (iv) by voting in person at the annual meeting. If any shares of common stock are held in a fiduciary, custodial or joint capacities, this proxy is signed by you in every such capacity as well as individually. This proxy, when executed, will be voted in the manner directed herein. If you do not specify below how you want the shares to be voted, this proxy will be voted FOR the election of Directors, and FOR Proposals 2 and 3. In their discretion, the Proxies are authorized to vote upon any other business that may properly come before the annual meeting or any adjournment(s) thereof. Please vote, date and sign on reverse side and return promptly in the enclosed pre-paid envelope. Your vote is important. Please vote immediately. (If you noted any Address Changes/Comments above, please mark corresponding box on the reverse side.) Continued and to be signed on reverse side V.1.1 Address Changes/Comments: